Document:

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                                                   EXHIBIT 10.9

                         LICENSE AND RESEARCH AGREEMENT

         THIS LICENSE AND RESEARCH AGREEMENT (the "Agreement") is made and
entered into as of 2 September, 1999, (the "Effective Date") by and between
Rigel Pharmaceuticals, Inc., a corporation organized under the laws of
Delaware and having a principal place of business at 240 East Grand Avenue,
South San Francisco, CA 94080 ("Rigel") and Cell Genesys, Inc. a corporation
organized under the laws of Delaware and having a principal place of business
at 342 Lakeside Drive, Foster City, CA 94404 ("CG"). Rigel and CG may be
referred to collectively as the "Parties," or individually as a "Party."

                                    RECITALS

         WHEREAS, CG owns patents relating to [ * ] cell lines [ * ] and [ * ]
cell lines [ * ], and related technology; and

         WHEREAS, Rigel has a license to the [ * ] cell lines, associated
vectors and vector libraries under intellectual property rights owned by
Stanford University; and

         WHEREAS, CG and Rigel desire to enter into an agreement granting each
other licenses under such patents and other intellectual property rights as
provided herein; and

         WHEREAS, Rigel is in the business of, among other things, providing
services for identifying molecules which bind together in intracellular
signaling pathways, and CG desires that Rigel perform such services for CG to
identify peptides, proteins and/or Genetic Material (as defined below) that
modulate angiogenesis in endothelial tissues.

         NOW THEREFORE, in consideration of the foregoing premises
and the covenants and promises contained in this Agreement, the
Parties agree as follows:

                                     ARTICLE 1

                                    DEFINITIONS

     1.1 "AFFILIATE" shall mean, with respect to a Party to this Agreement,
any other entity, whether de jure or de facto, which directly or indirectly
controls, is controlled by, or is under common control with, such Party. A
business entity or Party shall be regarded as in control of another business
entity if it owns, or directly or indirectly controls, at least fifty percent
(50%) (or such lesser percentage which is the maximum allowed to be owned by
a foreign entity in a particular jurisdiction) of the voting stock or other
ownership interest of the other entity, or if it

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                        1.

<PAGE>

directly or indirectly possesses the power to direct or cause the direction
of the management and policies of the other entity by any lawful means
whatsoever.

     1.2 "CG COLLABORATION PARTNERS" means those third parties which enter
into a research or development agreement with CG under which CG conducts
substantial research or development activities in collaboration with such
third party and grants a license to such third party under patents and/or
know-how owned or controlled by CG in addition to a sublicense under the
Rigel Biological Materials or Rigel Know-How, which licenses and sublicense
are for the further development and commercialization of the results of such
collaborative research or development.

     1.3 "CG [ * ] FIELD" means human Gene Therapy and animal Gene Therapy.

     1.4 "CG KNOW-HOW" means all Information Controlled by CG as of the
Effective Date that is necessary or useful for practicing the CG Patents.

     1.5 "CG LICENSE" means the license agreement between CG and [ * ] as in
effect as of the Effective Date and attached hereto as Appendix A.

     1.6 "CG PATENTS" means the Patents and applications listed on Appendix
B, to the extent the same as Controlled by CG.

     1.7 "CG PROGRAM FIELD" means the research, development or
commercialization of human or animal therapeutic products and services, which
products and/or services are comprised of peptides, proteins or Gene Therapy.

     1.8 "CONTROL" OR "CONTROLLED" means ownership of, or a license to, a
particular item, material or intellectual property right with the ability to
grant to the other Party access to and/or a license or sublicense as provided
for herein without violating the terms of any agreement with a Third Party
under which such rights were acquired from such Third Party.

     1.9 "FIELD OF RESEARCH" means identification of peptides, proteins and/or
Genetic Material that modulate angiogenesis in endothelial tissues.

     1.10 "FTE" means a full-time employee or consultant of Rigel or the
equivalent thereof.

     1.11 "FTE YEAR" means the amount of time one FTE would spend working during
one (1) calendar year.

     1.12 "GENE THERAPY" means a product or service for the treatment or
prevention of a disease that utilizes ex vivo or in vivo delivery (via viral
or nonviral gene transfer methods or systems) of Genetic Material, including
any cell incorporating Genetic Material.

     1.13 "GENETIC MATERIAL" means a nucleotide sequence, including DNA, RNA
and complementary and reverse complementary nucleotide sequences thereto,
whether coding or noncoding and whether intact or a fragment.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       2.
<PAGE>

     1.14 "INFORMATION" means any and all information, including without
limitation techniques, inventions, practices, methods, knowledge, know-how,
skill, experience, test data, analytical and quality control data, compositions
and assays, and any business, marketing, personnel or financial information or
matters.

     1.15 "PATENT" means an issued, valid, unexpired patent, including any
extension, registration, confirmation, reissue, re-examination or renewal
thereof, or a pending application for a patent, in any country, region or
jurisdiction.

     1.16 "PROGRAM KNOW-HOW" shall mean any Information developed in the
Research relating to the development of Therapeutic Candidates, excluding
Information relating to Targets.

     1.17 "PROGRAM PATENT" shall mean a Patent claiming inventions or
discoveries in the Program Know-How.

     1.18 "PROGRAM TECHNOLOGY" shall mean Program Know-How and Program
Patents.

     1.19 "RESEARCH" shall have the meaning provided in Section 3.1(a).

     1.20 "RESEARCH PLAN" shall have the meaning provided in Section 3.1(a).

     1.21 "RIGEL BIOLOGICAL MATERIALS" means the [ * ] cell lines, associated
vectors and vector libraries set forth in Appendix C.

     1.22 "RIGEL COLLABORATION PARTNERS" means those third parties which
enter into a research or development agreement with Rigel under which Rigel
conducts substantial research or development activities in collaboration with
such third party and grants a license to such third party under patents
and/or know-how owned or controlled by Rigel in addition to a sublicense
under CG Patents and/or CG Know-How, which licenses and sublicense are for
the further development and commercialization of the results of such
collaborative research or development.

     1.23 "RIGEL FIELD" means the creation and use of virally produced
peptide and protein libraries for the screening of transdominant effector
peptides and RNA molecules as claimed in the patent applications set forth on
Appendix D as well as any processes, techniques and applications disclosed in
the foregoing patents applications; it is understood that the foregoing
technology is to be used for (a) the discovery, validation and development of
targets for human or animal therapeutics, and (b) the discovery, testing,
development and commercialization of therapeutic, diagnostic and drug
delivery products. For purposes of this Section 1.23, "disclosed in" shall
mean disclosed in the specifications of such patent applications as necessary
to practice the invention claimed and not solely as part of the description
of the prior art.

     1.24 "RIGEL KNOW-HOW" means all Information Controlled by Rigel as of
the Effective Date necessary or useful for the use or modification of the
Rigel Biological Materials.

     1.25 "RIGEL LICENSE" means the license agreements between Rigel and
Stanford University as in effect as of the Effective Date and attached hereto
as Appendix E.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       3.
<PAGE>

     1.26 "RMC" shall have the meaning provided in Section 3.2.

     1.27 "SUCCESS CRITERIA" shall have the meaning provided in Section
3.1(b).

     1.28 "TAIL END PERIOD" shall mean the period of six (6) months after the
end of the Research Period, the purpose of which is to permit the RMC to
identify Therapeutic Candidates; provided, however, that if this Agreement is
terminated prior to or during the Tail End Period, the Tail End Period shall be
deemed to end upon such termination date.

     1.29 "TARGET" shall mean a molecule occurring naturally in the body that
is shown during the Research to directly or indirectly cause or impede
angiogenesis in endothelial tissue, to the extent such molecule (or its
binding to another molecule) is agonized or antagonized by a Therapeutic
Candidate. It is understood that a particular protein, peptide of Genetic
Material could be both a Therapeutic Candidate and a Target, and in such case
such molecule shall be treated as a "Target" hereunder to the extent that
such molecule is used as a drug discovery target, and shall at the same time
be treated as a "Therapeutic Candidate" hereunder to the extent such molecule
is used as a drug or therapy.

     1.30 "THERAPEUTIC CANDIDATE" shall mean a peptide, protein or Genetic
Material discovered, identified, produced or tested during the Research
Period pursuant to the Research, or identified during the Tail End Period,
which meets the Success Criteria, and any homologues or derivatives thereof.
For such purposes, it is understood that if a protein or peptide meets the
Success Criteria, Genetic Material that codes for such protein or peptide (or
its homologues or derivatives) shall be within the definition of Therapeutic
Candidate (and vice-versa).

     1.31 "[ * ] PATENTS" means the patents listed in Appendix F.

                                    ARTICLE 2

                                    LICENSES

     2.1   CG LICENSE GRANTS.

          (a) Subject to the terms of license of the CG License, CG hereby
grants to Rigel a royalty-free, non-exclusive, worldwide license, with the
right to sublicense to Rigel Collaboration Partners, under and to CG's right,
title and interest in any Program Technology owned solely by CG, all for
purposes solely within the Rigel Field; and hereby waives any claims against
Rigel for the practice and use of the CG Patents and CG Know-How within the
Rigel Field prior to the Effective Date. Any sublicense granted hereunder to
Rigel Collaboration Partners shall be limited to the purposes of such
collaboration (as such purposes are described in Section 1.22 above).

          (b) CG hereby grants to Rigel a royalty-free, exclusive, worldwide
license, with the right to grant and authorize sublicenses, under CG's right,
title and interest in the Program Technology that is owned jointly by the
Parties under Section 4.1(d) below, and Targets

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       4.
<PAGE>

that are similarly owned jointly with Rigel, all to make and use the Targets for
purposes outside the CG Program Field.

          (c) CG has entered into a license agreement with the [ * ] concerning
the [ * ] Patents which includes the right to sublicense (the "[ * ]
Agreement"); as of the Effective Date, however, the terms under which CG may
grant sublicenses under the [ * ] Agreement make impractical a sublicense to
Rigel under the [ * ] patents for purposes of the Rigel Field. In the event that
CG successfully renegotiates the terms of the [ * ] Agreement such that such
sublicense would be practical, CG agrees to discuss in good faith the grant of a
sublicense to Rigel under the [ * ] patents. The Parties understand and agree,
however, that CG is not and shall not be obligated to enter into any agreement
with Rigel concerning the [ * ] Patents, that failure to reach such an agreement
for any reason shall not be deemed a breach of this Agreement and that this
Section 2.1(C) shall not be deemed to preclude CG form entering into an
agreement with a third party of any type or at any time concerning the [ * ]
Patents.

     2.2   RIGEL LICENSE GRANTS.

          (a) Subject to the terms and prior to the termination or expiration of
the Rigel License, the Parties agree that Rigel shall grant to CG, at CG's sole
option and upon CG's request, a royalty-free, non-exclusive, worldwide license,
without the right to sublicense, under Rigel's right, title and interest in the
Rigel Know-How and Rigel Biological Materials, to make, have made, use sell,
offer for sale and import products in the CG [ * ] Field. It is understood that
in no event will CG have any obligation to obtain such license from Rigel. Rigel
will give CG thirty (30) days prior written notice of the termination of the
Rigel License by Rigel.

          (b)   Rigel hereby grants to CG:

               (i)    a royalty-free, exclusive, world-wide license, with the
right to grant and authorize sublicenses, under Rigel's right, title and
interest in the Program Technology (including without limitation the
Therapeutic Candidates) owned solely by Rigel or jointly with CG, to make,
have made, use, sell, offer for sale and import products, and otherwise
exploit the Program Technology, in each case for purposes solely within the
CG Program Field; and

               (ii)   subject to rights previously granted to third parties,
a royalty-free, non-exclusive, worldwide license, with the right to grant
sublicenses, under Rigel's right, title and interest in and to all Patents
with priority dates prior to the Effective Date that claim Therapeutic
Candidates, or the manufacture or use thereof, to make, have made, use and
sell products in Gene Therapy incorporating such Therapeutic Candidates.

          (c)   In addition, Rigel hereby grants to CG a royalty-free,
non-exclusive license, without the right to sublicense to CG Collaboration
Partners, under Rigel's right, title and interest in the Targets to make and
use the Targets solely to for the research and development of Therapeutic
Candidates in the Field of Research. For clarity, it is understood and agreed
that the licenses garanted to CG under this Section 2.2 specifically exclude
the performance by CG of research on or with a Target which is outside the
Field of Research. Any sublicense granted hereunder to CG Collaboration
Partners shall be limited to the purposes of such collaboration.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       5.
<PAGE>

     2.3  RIGEL COVENANT. Rigel hereby covenants that neither Rigel nor its
Affiliates will make any claims against CG, its permitted sublicensees,
distributors and customers in the chain of title with CG or its permitted
sublicensees for Patent infringement as a result of activities which are
explicitly permitted under the terms of this Agreement, nor shall Rigel or
its Affiliates authorize a third party to make such a claim, and Rigel agrees
to cooperate with CG in the defense against any such claim by licensees of
Rigel.

     2.4  NO OTHER LICENSE. No right or license is granted by either Party to
the other under any other intellectual property other than those items
expressly included in the licenses granted in this Article 2. Accordingly, no
license shall be deemed granted by implication, estoppel or otherwise, if
such license is not expressly and specifically granted in this Article 2.

                                    ARTICLE 3

                                    RESEARCH

     3.1  RESEARCH.

          (a) Rigel agrees to (i) use diligent efforts to conduct research
within the Field of Research (the "Research"), in accordance with the
research plan (the "Research Plan") incorporated hereby in, and appended to,
this Agreement as Appendix G, as amended from time to time by written
agreement of the Parties; and (ii) use diligent efforts to meet the goals of
the Research Plan according to the timetables set forth therein. Without
limiting the foregoing, the Research shall commence of the Effective Date and
terminate upon the earlier of three (3) years after the Effective Date or the
termination of the Agreement (the "Research Period"). Rigel will commit [ * ]
during each year of the Research Period, or such other allocation as the RMC
may decide, provided that in the event the RMC decides to reallocate FTEs
between years, Rigel shall have no obligation to commit more than [ * ] in
total over the entire Research Period. The individual FTEs who will conduct
the Research are listed in Appendix H and may be replaced by Rigel, as
reasonably agreed by the Parties, with other FTEs of comparable skill and
expertise. Rigel agrees to test against the Success Criteria during the
Research Period any proteins, peptides and Genetic Material produced or
evaluated in connection with the Research as contemplated in the Research
Plan.

          (b) The Parties shall reasonably establish criteria for determining
whether a particular peptide, protein or Genetic Material modulates
angiogenesis in endothelial tissue in assays performed at Rigel, as such
criteria are contemplated in the Research Plan (the "Success Criteria").

     3.2  RESEARCH MANAGEMENT COMMITTEE. The Parties shall form a research
management committee (the "RMC") comprised of four (4) individuals, two (2)
being Rigel employees appointed and replaced by Rigel at its discretion, and
two (2) being CG employees appointed and replaced by CG at its discretion.
The size and composition of the RMC may be modified by mutual agreement of
the Parties. The RMC shall evaluate the results of the Research set forth in
the research reports pursuant to Section 3.4(a) to assess whether a peptide,
protein or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       6.
<PAGE>

Genetic Material is a Therapeutic Candidate, and perform such other duties as
specifically delegated to the RMC by mutual written agreement of the Parties.

     3.3  RMC MEETINGS AND ACTIONS. RMC Meetings shall take place at such
times and places as shall be determined by the RMC in order for the RMC to
fulfill its obligations under Section 3.2. It is expected that the meetings
will alternate between appropriate offices of each Party, or at such other
convenient locations as agreed. If agreed by its members, the RMC may conduct
meetings by telephone or video conference or other acceptable electronic
means, provided that any decisions made during such meeting are recorded in
writing and confirmed by signature of at least one (1) of the RMC members
from each of the Parties. All decisions of or actions taken by the RMC shall
be by unanimous approval of all the members of the RMC, and voting on any
matters shall be reflected in the minutes of the meeting at which the vote
was taken. If the RMC is unable to reach unanimous decision on any particular
matter or issue, such matter or issue shall be referred to the chief
executive officer of each Party or their designees for resolution. It is
understood that for purposes of determining the Parties' rights and
obligations under this Agreement, the authority of the RMC shall be limited
to deciding those specific issues specifically delegated to the RMC in other
Article of this Agreement (i.e., other than the general matters described in
this Article 3).

     3.4  REPORTS; DISCLOSURE.

          (a) Rigel shall keep CG fully informed of the progress and results
of the Research and shall provide written reports at or before each RMC
meeting describing its activities, the level of effort applied to, and the
results of, the Research, specifically including Rigel's determination as to
which peptides, proteins or Genetic Material as of the date of such report
meet the Success Criteria. Such RMC reports shall be in such form and contain
such detail as the RMC shall determine. Rigel agrees to fully disclose to CG
the Program Technology and the Targets, and to provide CG with reasonable
quantities of Targets and Therapeutic Candidates generated or utilized in
connection with the Research.

          (b) Rigel agrees to maintain records of its activities in
performing the Research, in good scientific manner, and to permit CG to have
access to such records upon ten (10) days written notice to Rigel and during
regular business hours, to the extent reasonably necessary to verify that
Rigel has met its obligations under this Section 3.4.

     3.5  EXCLUSIVITY OF EFFORTS. Rigel agrees that neither Rigel nor any of
its Affiliates shall directly or indirectly conduct or sponsor any research,
develop or otherwise commercialize any products or technologies within the
Field of Research, other than pursuant to the Research Plan, during the
Research Period and for a period of [ * ] following the Research Period.
Without limiting the foregoing, Rigel shall not appoint or license any third
party to develop market, sell or otherwise distribute such products until
after the expiration of [ * ]following the Research Period.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       7.
<PAGE>

                                    ARTICLE 4

                          INTELLECTUAL PROPERTY MATTERS

     4.1   OWNERSHIP AND PROSECUTION. Subject to the terms of this Agreement,
as between the Parties hereto:

          (a) It is understood that CG retains its entire right, title and
interest in the CG Patents and CG Know-How, subject only to the rights
expressly granted to Rigel hereunder, and shall have the right, but not the
obligation, to file, prosecute and maintain any Patents related thereto at
its expense.

          (b) It is understood that Rigel retains its entire right, title and
interest in the Rigel Biological Materials and Rigel Know-How, subject only
to the rights expressly granted to CG hereunder, and shall have the right,
but not the obligation, to file, prosecute and maintain any Patents related
thereto at its expense.

          (c) It is understood that, subject only to the rights expressly
granted to the other Party hereunder, each Party retains its entire right,
title and interest in and to any inventions, discoveries, know-how, trade
secrets, and other information made or developed solely by such Party and/or
its consultants in the course of the performance of this Agreement ("Sole
Inventions"), and, subject to subsection (e) below, shall have the right, but
not the obligation, to file, prosecute and maintain any Patents claiming its
Sole Inventions ("Sole Patents") in all countries of the world.

          (d) Both Parties shall jointly own any inventions, discoveries,
know-how, trade secrets, and other information, that are made jointly by the
Parties in the course of the performance of this Agreement ("Joint
Inventions"). Subject to subsection (e) below, the RMC shall designate the
Party which shall be responsible for filing, prosecuting and maintaining
Patents claiming Joint Inventions ("Joint Patents"). All costs and expenses
of filing, prosecuting and maintaining such Joint Patents will be borne
equally by the Parties. The Party designated by the RMC to perform patenting
activities shall seek the comments of the other Party and shall keep the
other informed of the progress of such prosecution by providing quarterly
status reports and copies of all correspondence between their patent counsel
and the patent offices of the countries where such applications were filed.
Such other Party shall reasonably assist the Party designated by the RMC in
the prosecution of Joint Patents, including, without limitation, by executing
any necessary powers of attorney. Subject to the rights and licenses granted
to the other Party in Section 2.1(b) and 2.2(b), it is understood that
neither Party shall have any obligation to account to the other, or obtain
the consent of the owner, with respect to the commercialization, licensing or
enforcement of any Joint Patents, and hereby waives any right it may have
under the laws of any country to require such accounting or consent.

          (e) CG shall have the right but not the obligation (either itself or
through its designee) to file, prosecute and maintain Patents claiming
Therapeutic Candidates ("Candidate Patents"); provided, however, that for any
molecule that is a Therapeutic Candidate and a Target: (i) CG shall have the
right but not the obligation (either itself or through its designee) to file,
prosecute and maintain Patents claiming uses of such molecule in the CG Program
Field and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       8.
<PAGE>

such Patents also shall be Candidate Patents; and (ii) Rigel shall have the
right, but not the obligation, to file, prosecute and maintain any patents
claiming the composition of matter of such molecule or claiming any use of
the molecule outside the CG Program Field or in the Rigel Field. All costs
and expenses of filing, prosecuting and maintaining Candidate Patents will be
borne by the Party that undertakes such prosecution. The Party undertaking
such prosecution shall seek the comments of the other Party and shall keep
the other Party informed of the progress of such prosecution by providing
quarterly status reports and copies of all correspondence between their
patent counsel and the patent offices of the countries where such
applications were filed. Each Party shall reasonably assist the other Party
in the prosecution of Candidate Patents, including, without limitation, by
executing any necessary powers of attorney and other document, necessary for
such prosecution.

          (f) Each Party agrees to keep the other Party fully informed as to
prosecution and maintenance (including without limitation any interference,
opposition or other prosecution or other proceedings) with respect to patents
claiming and disclosing subject matter within the Program Technology. In the
event that a Party elects not to prosecute or maintain any patent rights in a
Sole Invention comprising Program Technology, it shall promptly notify the
other Party and authorize the other Party to seek or continue such
prosecution and maintenance at such other Party's expense. In such case the
owner of Sole Invention shall cooperate fully with the other Party to
facilitate such prosecution and maintenance.

     4.2  INFRINGEMENT AND SIMILAR ACTIONS.  As between the Parties hereto:

          (a) CG shall have the sole and exclusive right, at its expense, to
prosecute any and all infringement or wrongful use of the CG Patents and CG
Know-How, and (subject to paragraph (c) below) Sole Patents owned by CG
and/or to enter settlements, judgments or other arrangements respecting such
infringement or wrongful use. CG may retain all damages and other amounts
recovered as a result of any such action, settlement, judgment or other
arrangement.

          (b) Rigel shall have the sole and exclusive right, at its expense,
to prosecute any and all infringement or wrongful use of the Rigel Know-How,
the Rigel Biological Materials, and (subject to paragraph (c) below) Sole
Patents owned by Rigel and/or to enter settlements, judgments or other
arrangements respecting such infringement or wrongful use. Rigel may retain
all damages and other amounts recovered as a result of any such action,
settlement, judgment or other arrangement.

          (c) With respect to infringement of any Program Patents in the CG
Program Field, CG shall have the right, but not the obligation (directly or
through designees), to institute, prosecute and control at its own expense
and for its own benefit, any action or proceeding with respect to such
infringement. With respect to infringement of any Program Patents (i.e.,
outside the CG Program Field), Rigel shall have the right, but not the
obligation, (directly or through designees) to institute, prosecute and
control, at its own expense and for its own benefit, any action or proceeding
with respect to such infringement. If a Party with the right to do so fails
to bring an action or proceeding against a suspected infringer within a
reasonable period after receiving a written request by the other Party to do
so, such other Party shall have the right to

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       9.
<PAGE>

bring and control an action against such infringer by counsel of its own choice
and retain for its own account any amounts recovered from third parties. If one
Party brings any such action or proceeding, the other Party agrees to be joined
as a Party plaintiff if necessary to prosecute the action and to give the first
Party reasonable assistance and authority to file and prosecute the suit.

          (d) Each Party shall promptly notify the other in writing of any
alleged or threatened infringement of Joint Patents of which it becomes aware
and which may adversely impact the rights of the Parties hereunder. Promptly
upon such notification, the Parties shall meet to discuss the strategy and
appropriate steps to be taken to deal with such infringement. Any recovery
obtained by settlement or otherwise shall be disbursed as follows: first, any
reasonable expenses incurred in connection with such action (including counsel
fees) by both Parties are reimbursed; thereafter, the net recovery shall be
shared between the Parties according to the ratio of their respective
contributions to the litigation costs. This paragraph shall not be deemed to
limit the Parties' respective rights to enforce Joint Patents, or to limit the
rights granted under paragraph (c) above.

     4.3  THIRD PARTY CLAIMS.

          (a) Except to the extent expressly warranted in Article 7, and
subject to the indemnification obligation in Article 5, CG shall have no
liability to Rigel with respect to any claim, suit or action alleging that
the practice of the license rights granted by CG under Section 2.1 infringes
any intellectual property or other right of a third party. Except to the
extent expressly warranted in Article 7, and subject to the indemnification
obligation in Article 5, Rigel shall have no liability to CG or its
Affiliates with respect to any claim, suit or action alleging that the
practice of the license rights granted under Section 2.2 infringes any
intellectual property or other rights of a third party.

          (b) Rigel hereby agrees to provide reasonable assistance to CG, at
its request, in defending any action or claim initiated by a third party
against CG arising from any claim that the use or practice of the Rigel
Know-How, Rigel Biological Materials or the Target by CG or its Affiliates
infringes that third party's proprietary rights. CG hereby agrees to provide
Rigel reasonable assistance, at its request and expense, in defending any
action or claim initiated by a third party against Rigel or its Affiliates
arising from any claim that the use or practice of the CG Patents or CG
Know-How by Rigel or its Affiliates infringes that third party's proprietary
rights.

          (c) If a third party asserts against CG that a patent, trademark or
other intangible right owned by it is infringed by any product in the CG
Program Field derived or resulting from or incorporating Program Technology,
CG will be solely responsible for defending against any such assertions at
its cost and expense. Each Party will give prompt written notice to the other
of any such claim. Rigel will assist in the defense of any such claim as
reasonably requested by CG, at CG's expense, and may retain separate counsel
at its own expense at any time.

          (d) Neither Party shall enter into any settlement of any such claim
which would admit the invalidity of Patents within the Program Technology
without the other Party's prior written consent, which consent shall not be
unreasonably withheld or delayed.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                      10.

<PAGE>

     4.4   PASS-THROUGH ROYALTIES.  In consideration for the
licenses granted herein:

           (a) Rigel agrees to pay any amounts which CG is required to pay to
[ * ] under the CG License as a result of CG's grant to Rigel of license
rights to CG Patents or CG Know-How to Rigel or the exercise of the license
rights granted by CG under the CG License.

           (b) Rigel agrees to pay CG (i) [ * ] for the license granted to
Rigel hereunder to CG Patents related to the [ * ] cell lines, and (ii) [ * ]
for each sublicense granted by Rigel under this Agreement.

           (c) CG agrees that in the event CG exercises its option to obtain a
license pursuant to Section 2.2(a) above, CG will pay any amounts which Rigel
is required to pay to Stanford University under the Rigel Licesne as a result
of Rigel's grant to CG of license rights to Rigel Biolgoical Material or
Rigel Know-How to CG or the exercise of the license rights granted by Rigel
under the Rigel License. It is understood that unless and until CG obtains
such license rights from Rigel, CG shall not be obligated to pay to Rigel or
to Stanford University any amounts that Rigel is required to pay to Stanford
University under the Rigel License.

                                    ARTICLE 5

                                 INDEMNIFICATION

     5.1   CG INDEMNITY. CG agrees to indemnify, hold harmless and defend
Rigel, its Affiliates, agents and employees from and against any and all
liabilities, losses, damages, costs, fees and expenses, including reasonable
legal expenses and attorneys' fees (collectively, "Losses") arising out of
suits, claims, actions, or demands, brought or made by a third party ("Third
Party Claim") against Rigel, its Affiliates, agents and employees, based on
(i) CG's use and practice of the Rigel Know-How, Rigel Biological Materials,
the Program Technology or the Targets, or (ii) breach of CG's warranties
under Article 7 below, or (iii) the manufacture, use, handling, storage, sale
or other disposition of Rigel Biological Materials, Program Technology, the
Targets or any products resulting or derived from the Rigel Biological
Materials or the Program Technology by CG, it Affiliates, agents, employees
or sublicensees, all except to the extent such Losses or Third Party Claims
result from the negligence or willful misconduct of Rigel or a breach of
Rigel's warranties under Article 7 below.

     5.2   RIGEL INDEMNITY. Rigel agrees to indemnify, hold harmless and
defend CG, its Affiliates, agents and employees from and against any and all
Losses arising out of any Third Party Claims against CG, its Affiliates,
agents and employees based on (i) Rigel's use or practice of the CG Patents
the CG Know-How or the Program Technology, (ii) breach of Rigel's warranties
under Article 7 below, or (iii) the manufacture, use, handling, storage, sale
or other disposition of Program Technology, the Targets or any products
resulting or derived from the Program Technology by Rigel, its Affiliates,
agents, employees or sublicensees, all except to the extent such Losses or
Third Party Claims result from the negligence or willful misconduct of CG, or
a breach of CG's warranties under Article 7 below.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                      11.

<PAGE>

     5.3   In the event that a Party is seeking indemnification under this
Article 5, it shall inform the other Party of a claim or suit as soon as
reasonably practicable after it receives notice of the claim or suit, shall
permit the indemnifying Party to assume direction and control of the defense
of the claim or suit (including the right to settle the claim or suit solely
for monetary consideration), and shall cooperate as reasonably requested (at
the expense of the indemnifying Party) in the defense of the claim or suit.
Neither Party will enter into any settlement or claim pursuant to this
Section 5.3 which is materially adverse to the rights of the other Party
herein, without the other Party's prior written consent, which will not be
unreasonably withheld or delayed.

                                    ARTICLE 6

                                 CONFIDENTIALITY

     6.1   CONFIDENTIALITY. Except to the extent expressly authorized by this
Agreement or otherwise agreed in writing, the Parties agree that, for the
term of this Agreement and for five (5) years thereafter, the Party receiving
any Information or materials furnished to it by the other Party pursuant to
this Agreement (collectively, "Confidential Information") shall keep
confidential and shall not publish or otherwise disclose or use such
Confidential Information for any purpose other than as provided for in this
Agreement.

     6.2   EXCEPTIONS. The obligations in Section 6.1 shall not apply to any
Information or materials to the extent that the receiving Party can establish
by competent proof that such Information or materials:

           (a)   was already known to the receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the other Party;

           (b)   was generally available to the public or otherwise part of
the public domain at the time of its disclosure to the receiving Party;

           (c)   became generally available to the public or otherwise part of
the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement; or

           (d)   was disclosed to the receiving Party, other than under an
obligation of confidentiality, by a Third Party who had no obligation to the
disclosing Party not to disclose such information to others.

      6.3  AUTHORIZED DISCLOSURE. Each Party may disclose the other's
Confidential Information to the extent such disclosure is reasonably
necessary (i) to exercise the rights granted to such Party hereunder
(including the right to grant sublicenses as permitted by this Agreement
provided that prior to any disclosure to a sublicensee, such sublicensee has
executed a confidentiality agreement with terms corresponding to this Article
6); and (ii) to file or prosecute patent applications, to prosecute or defend
litigation, to comply with applicable governmental

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      12.

<PAGE>

regulations or to conduct preclinical or clinical trials; provided that if a
Party is required by law or regulation to make any such disclosure of the
other Party's Confidential Information it will, except where impracticable
for necessary disclosures, for example in the event of medical emergency,
give reasonable advance notice to the other Party of such disclosure
requirement and, except to the extent inappropriate in the case of patent
applications, will use its best efforts to secure confidential treatment of
such Confidential Information required to be disclosed.

      6.4  SURVIVAL. This Article 6 shall survive the termination or
expiration of this Agreement for a period of five (5) years.

                                    ARTICLE 7

                                WARRANTY MATTERS

      7.1  LIMITED WARRANTIES. CG hereby represents and warrants to Rigel that
CG has the full right and power to grant the licenses granted to Rigel under
Section 2.1(a). Rigel hereby represents and warrants to CG that Rigel has the
full right and power to grant the licenses granted to CG under Section 2.2.

     7.2   GENERAL WARRANTIES. Each of the Parties hereby represents and
warrants to the other that (i) it is a corporation duly organized and validly
existing in good standing under the laws of its state of incorporation, (ii)
it is duly qualified and authorized to enter into and perform its obligations
under this Agreement, (iii) it has full power, authority and legal right to
enter into and perform this Agreement, and (iv) the execution, delivery, and
performance of this Agreement has been duly authorized by all necessary
corporate action on the part of each Party and does not contravene any law
binding on it, its Articles of Incorporation or Bylaws, any indenture,
mortgage, contract or other agreement to which it is a Party or by which it
is bound or any laws, governmental rule, regulation or order.

     7.3   INTELLECTUAL PROPERTY WARRANTIES.

           (a)   Each of the Parties hereby represents and warrants to the
other that (i) it does not Control any Patens that would dominate the Patents
licensed to the other Party hereunder, (ii) it is not aware of any claims of
a third party which would call into question the rights of such Party in the
licensed subject matter or its right to grant the licenses granted to the
other Party hereunder, (iii) it has provided the other Party with all
information concerning royalty obligations pertinent to the licenses granted
to the other Party hereunder; and (iv) it will use commercially reasonable
efforts to keep in force any license agreement from which the license or
sublicense granted to the other Party under this Agreement is derived to the
extent that such license agreement does not provide for a survival of any
sublicenses granted by such Party.

           (b)   Rigel further warrants to CG that as of the Effective Date
(i) to the best of its knowledge, Rigel's conduct of the Research, and the
manufacture, sale and use of Therapeutic Candidates will not infringe any
third party intellectual property rights, and without limiting the foregoing,
Rigel warrants that Rigel's conduct of the Research will not infringe any of
the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      13.

<PAGE>

patents listed in Appendix I hereto; (ii) Rigel does not know of any third
party other than Stanford University having a claim in the Rigel Biological
Materials; and (iii) Rigel has the right to grant to CG a license under the
Rigel Biological Materials and the Rigel Know-How to make, use and sell
products in the CG [ * ] Field.

           (c)   CG further warrants to Rigel that CG has the right to grant
to Rigel a license under the CG Patents and CG Know-How to make, use and sell
products within the Rigel Field.

           (d)   Rigel warrants that it has not as of the Effective Date
entered into an agreement with any third party licensing or granting right to
Rigel technology in the Field of Research.

     7.4   LIMITATION ON WARRANTIES. EXCEPT AS PROVIDED IN SECTIONS 7.1, 7.2,
AND 7.3 ABOVE, NEITHER PARTY MAKES ANY WARRANTIES TO THE OTHER PARTY, WHETHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AS TO ANY PRODUCT OR
PROCESS, OR AS TO THE VALIDITY OR SCOPE OF ANY PATENTS, OR THAT ANY LICENSED
BIOLOGICAL MATERIALS, PATENTS OR KNOW-HOW WILL BE FREE FROM INFRINGEMENT OF
PATENTS OF ANY THIRD PARTY, OR THAT NO THIRD PARTIES ARE INFRINGING SAME.

                                    ARTICLE 8

                              TERM AND TERMINATION

     8.1   TERM OF AGREEMENT. Unless earlier terminated as otherwise provided
in this Article 8, this Agreement shall remain in effect until the expiration
of the last to expire of the CG Patents or Program Patents.

     8.2   TERMINATION FOR BREACH. A Party may terminate this Agreement prior
to the expiration of the Agreement in the event that the other Party is in
breach of or default under a material term of the Agreement, and the
breaching Party does not cure such breach or default within thirty (30) days
of written notice thereof from the non-breaching Party. Subject to Section
8.3 below, upon any such termination, all the licensees granted by and
between the Parties herein shall terminate; provided that any sublicense
granted by a Party hereunder to a third party prior to such termination shall
survive such termination, so long as the sublicensee agrees to be bound by
the applicable terms of this Agreement.

     8.3   SURVIVAL. Upon expiration or termination of this Agreement the
rights and obligations under Articles 5 and 6 and Sections 7.4, 8.3, 9.2,
9.3, 9.7 and 9.10 shall continue. In addition, upon expiration or termination
of this Agreement after the end of the Research Period, the license granted
under Article 2 above and the rights and obligations under Article 4 shall
survive. Further, subject to Section 2.1(b) and 2.2(b) if they survive the
termination or expiration of this Agreement as provided above, neither Party
shall have any obligation to account to the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      14.

<PAGE>

other, or obtain the consent of the owner, with respect to the
commercialization, licensing or enforcement of any Joint Patents, and hereby
waives any right it may have under the laws of any country to require such
accounting or consent.

                                    ARTICLE 9

                                  MISCELLANEOUS

     9.1   RELATIONSHIP OF THE PARTIES. This Agreement creates only
licensor-licensee and sublicensor-sublicensee relationships between Rigel and
CG. No partnership or other legal relationship is created hereunder. Neither
Party is, or will be deemed to be, an agent or legal representative of the
other Party for any purpose. Neither Party will be entitled to enter into any
contracts in the name of or on behalf of the other Party, and neither Party
will be entitled to pledge the credit of the other Party in any way or hold
itself out as having authority to do so.

     9.2   ASSIGNMENT. This Agreement may not be assigned by either Party
without the prior written consent of the other Party, which consent shall not
be unreasonably withheld; provided, however, that a Party may assign this
Agreement without such consent to any Affiliate or to a successor in interest
by way of merger, acquisition, sale or transfer of substantially all of its
business or assets pertaining to the subject matter of this Agreement. The
Agreement will be binding upon and inure to the benefit of all permitted
successors and assignees of the Parties hereunder, and the name of each Party
appearing herein will be deemed to include the names of such Party's
successors and assignees.

     9.3   USE OF NAMES. No Party hereto may use the name of the other Party
in public announcements without the prior consent of the other Party as
required by law or regulation.

     9.4   AMENDMENT. No amendment, modification or supplement of any
provision of the Agreement will be valid or effective unless made in writing
and signed by a duly authorized officer of each Party.

     9.5   WAIVER. No provision of the Agreement will be waived by any act,
omission or knowledge of a Party or its agents or employees except by an
instrument in writing expressly waiving such provision and signed by a duly
authorized officer of the waiving Party.

     9.6   HEADINGS. The headings for each article and section in this
Agreement have been inserted for the convenience of reference only and are
not intended to limit or expand on the meaning of the language contained in
the particular article or section.

     9.7   NOTICES. Any notice or other communication required or permitted to
be given to either Party hereto shall be in writing unless otherwise specified
and shall be deemed to have been properly given and to be effective on the date
of delivery if delivered in person or by facsimile or three (3) days after
mailing by registered or certified mail, postage paid, to the other Party at
the following address:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      15.

<PAGE>

If to Rigel:      Rigel, Inc.
                  240 East Grant Avenue
                  South San Francisco, CA  94080
                  Attn: Secretary
                  Fax: 650.624.1101

Copy to:          Cooley Godward, LLP
                  Five Palo Alto Square, 4th Floor
                  3000 El Camino Real
                  Palo Alto, CA  94306
                  Attn: Patrick A. Pohlen, Esq.
                  Fax: 650.857.0663

If to CG:         Cell Genesys, Inc.
                  342 Lakeside Drive
                  Foster City, CA 94404
                  Attn: Chief Executive Officer
                  Fax: 650.358.0803

     9.8   SEVERABILITY. Whenever possible, each provision of the Agreement
will be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of the Agreement is held to be
prohibited by or invalid under applicable law, such provision will be
ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of the Agreement.

     9.9   ENTIRE AGREEMENT OF THE PARTIES. The Agreement will constitute and
contain the complete, final and exclusive understanding and agreement of the
Parties with respect to the subject matter hereof and cancels and supersedes
any and all prior negotiations, correspondence, understandings and
agreements, whether oral or written, between the Parties respecting the
subject matter. Each Party hereto was represented by counsel in drafting and
negotiating this Agreement, and all Parties are deemed to have contributed to
the drafting hereof.

     9.10  GOVERNING LAW. This Agreement shall be governed by and construed
in accordance with the laws of the State of California excluding only laws
and rules relating to "choice of law". All Parties to this Agreement hereby
consent to the jurisdiction of the courts of the State of California and the
Federal District Court for the Northern District of California for resolution
of any disputes that arise hereunder.

     9.11  COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      16.

<PAGE>

         IN WITNESS WHEREOF, the Parties hereto have duly executed this
Agreement as of the date first written above.

CELL GENESYS, INC.                          RIGEL PHARMACEUTICALS, INC.

By:      /s/ Stephen A. Sherwin             By:     /s/ Donald W. Perryman
   --------------------------------------      -------------------------------
Name:        Stephen A. Sherwin, M.D.       Name:       Donald W. Perryman
     ------------------------------------        -----------------------------
Title: Chairman & Chief Executive Officer   Title: VP, Business Development
      -----------------------------------         ----------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      17.

<PAGE>

                                   APPENDIX A
                           EXCLUSIVE LICENSE AGREEMENT

           EXCLUSIVE LICENSE AGREEMENT made as of January 31, 1996 (the
"Effective Date"), by and between Cell Genesys, Inc. ("Company"), a
corporation organized and existing under the laws of the State of Delaware,
having an office at 322 Lakeside Drive, Foster City, California 94404, and
[ * ] ("[ * ]"), a nonprofit education corporation organized and existing
under the laws of the State of New York, having an office at [ * ]

                                   WITNESSETH:

           WHEREAS, [ * ] is the owner by assignment from [ * ] ("Inventors")
of the entire right, title and interest in United States Patent Application
[ * ]and in the inventions described and claimed therein ("Licensed Patent
Rights"), and in the Biological Materials and related Know-How, as defined
below;

           WHEREAS, [ * ] and the Company entered into a license agreement
effective as of October 25, 1994 (the "Prior Agreement"), pursuant to which
[ * ] granted to the Company a non-exclusive license to use the Licensed
Patent Rights, Know-How and Biological Materials for research and commercial
purposes;

           WHEREAS, the parties have agreed to expand the scope of the license
and rights granted to the Company and therefore have agreed to terminate the
Prior Agreement as of the Effective Date, and enter into this Agreement;

           WHEREAS, [ * ] wishes to offer and grant the Company an exclusive
license with regard to the Licensed Patent Rights, Know-How and the
Biological Materials for research and commercial purposes, and seeks to be
compensated for the transfer and use of such rights; and

           WHEREAS, the Company wishes to license from [ * ] the Licensed
Patent Rights, Biological Materials and Know-How for commercial development
and application as herein defined.

           NOW, THEREFORE, in consideration of the mutual benefits to be
derived hereunder, the parties hereto agrees as follows:

1.         DEFINITIONS.

         The following terms will have the meanings assigned to them below
when used in this Agreement.

     1.1   "AFFILIATE" shall mean:

           (a) any entity owning or controlling, directly or indirectly, at
least forty-nine percent (49%) of the stock normally entitled to vote for
election of directors of a party; or

           (b) any entity at least forty-nine percent (49%) of whose stock
normally entitled to vote for election of directors is owned or controlled,
directly or indirectly, by a party.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      1.

<PAGE>

     1.2   "BIOLOGICAL MATERIALS" shall mean (i) the ecotropic producer cell
line named [ * ] which producer cell line was deposited with the American
Type Culture Collection as of [ * ] and has been assigned
Accession No. [ * ] and any viruses produced thereby; (ii)
__________________________________________________ Biological Materials shall
also include any direct progeny, mutant, or derivatives of the [ * ]
_____________________________________________ cell lines and the viruses
produced thereby.

     1.3   "IMPROVEMENT TECHNOLOGY" means all patent and other intellectual
property rights, and materials relating to inventions, discoveries or
improvements to the Licensed Technology licensed to [ * ] by any academic
institution, governmental and other not-for-profit entity to which [ * ]
grants a non-exclusive research license with regard to the Licensed
Technology pursuant to Section 6.3 herein.

     1.4   "KNOW-HOW" shall mean information and data not generally known which
are owned and in the possession of or available to [ * ] and which it is free
to divulge as of the Effective Date regarding the preparation and use of
Biological Materials, and pharmacological, biological and clinical properties
of Biological Materials. It is understood that Know-How shall not include any
information or data known by the Company prior to receipt of such information
or data from Rockefeller, as shown by reasonable evidence.

     1.5   "LICENSED PATENT RIGHTS" shall mean:

           (a)   the patent application(s) concerning the subject matter of
this Agreement which are listed on Exhibit A attached hereto;

           (b)   all patent applications which are divisions, substitutions,
continuations, continuations-in-part, renewals, or additions of the patent
applications described in (a) hereof,

           (c)   all foreign counterparts of the applications listed in (a)
and (b) hereof; and

           (d)   all patents, including reissues, re-examinations and
extensions, which may issue on any of the preceding.

     1.6   "LICENSED PRODUCTS" shall mean any and all products the manufacture,
use or sale of which but for the license granted herein would infringe a Valid
Claim or are within the scope of a Pending Claim in the country in which such
products are made or sold.

     1.7   "LICENSED TECHNOLOGY" shall mean the Licensed Patent Rights,
Biological Materials and Know-How.

     1.8   "NET SALES" shall mean [ * ], where [ * ] shall mean the amount
invoiced by the Company or its sublicensees to customers for Licensed Products
less: (i) all trade, cash and quantity credits, discounts, refunds or
government rebates, (ii) amounts for claims, allowances or credits for returns;
retroactive price reductions; chargebacks or the like; (iii) packaging,
handling fees and prepaid freight, sales taxes, duties and other governmental
charges (including value added tax), but excluding what is commonly known as
income taxes; and (iv) provisions for

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       2.

<PAGE>

uncollectible accounts determined in accordance with reasonable accounting
practices, consistently applied to all products of the selling party. [ * ]
shall not include sales by the Company to its Affiliates for resale, provided
that if the Company sells a Licensed Product to an Affiliate for resale, [ * ]
shall include the amounts invoiced by such Affiliate to third parties on the
resale of such Licensed Product. Notwithstanding the foregoing. [ * ] shall
include charges for the separation, transduction and/or expansion of cells
comprising Licensed Products, but notwithstanding any of the foregoing, shall
not include charges for apheresis, reinfusion, surgical procedures, hospital
stays or other charges not directly attributed to the Licensed Product or to
the ex vivo preparation of the Licensed Product.

     1.9   "PARTY" shall mean the Company or [ * ], and "Parties" shall mean
both the Company and Rockefeller.

     1.10  "PENDING CLAIM" shall mean a claim of a pending patent application
within the Licensed Patent Rights.

     1.11  "TERRITORY" shall mean the entire world.

     1.12  "VALID CLAIM" shall mean a claim of an issued and unexpired patent
included within the Licensed Patent Rights, which has not been held
unenforceable or invalid by a court or other governmental agency of competent
jurisdiction, and which has not been admitted to be invalid or unenforceable
through reissue, disclaimer or otherwise.

2.   LICENSED RIGHTS

     2.1   Subject to Section 2.2 below, [ * ] grants to the Company and its
Affiliates the following licenses:

           (a)  an exclusive, worldwide, royalty-bearing license under the
Licensed Technology, with the right to grant and authorize sublicenses, to
make, have made, import, have imported, use, sell, offer for sale and
otherwise exploit the Licensed Products in any country of the Territory; and

           (b)  a non-exclusive, worldwide, royalty-free, irrevocable license
under the Improvement Technology, with the right to grant and authorize
sublicenses, to make, have made, import, have imported, use, sell, offer for
sale and otherwise commercialize products and services in any country of the
Territory.

     2.2   The licenses granted by [ * ] in Section 2.1 (a) above are subject
to any limitations on [ * ] rights arising under the provisions of the
following:

           (a)  35 United States, Section 201 et seq., and regulations and
rules promulgated thereunder and any agreements implementing the provisions
thereof, or

           (b) other applicable laws or regulations to which [ * ] may be
subject; or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       3.

<PAGE>

           (c)  [ * ] Institutional Patent Agreement with the United States
Department of Health and Human Services, dated June 15, 1973, as amended,
which is its formal agreement with the United States Government to implement
the cited provisions of the U.S. Code.

     2.3   [ * ] shall promptly notify the Company of any Improvement
Technology of which it acquires knowledge and provide the Company all
available information relating thereto.

     2.4   The licenses herein granted shall continue for the lives of any
issued patents hereunder as the same or the effectiveness thereof may be
extended by any governmental authority, rule or regulation applicable thereto.

3.   TRANSFER OF BIOLOGICAL MATERIALS AND KNOW-HOW

     3.1   The parties acknowledge that pursuant to the Prior Agreement, [ * ]
transferred to the Company a quantity of Biological Materials and such Know-How
to allow the Company to establish a viable cell culture of said Biological
Materials for the Company's purposes. The Company is permitted to cultivate and
use said Biological Materials, subject to the terms and conditions of this
Agreement On the Effective Date, [ * ] shall notify the American Type Culture
Collection ("ATCC") that the Company is authorized to receive samples of the
Biological Materials deposited with the ATCC and to deliver such materials to
the Company at the Company's request, and that the Company has the right to
authorize third parties to receive one or more samples of the Biological
Materials, on such terms as the Company may indicate to the ATCC.

     3.2   Should the Company exhaust the quantity of Biological Materials
within six (6) months of the date of execution hereof, so that a viable cell
culture of said Biological Materials no longer exists, [ * ] shall authorize
the ATCC to provide the Company with a quantity of Biological Materials
sufficient to reestablish the Company's viable colony thereof.

     3.3   Within sixty (60) days of the Effective Date, [ * ]shall deliver
to the Company tangible copies of all existing Know-How which it did not
previously provide to the Company pursuant to the Prior Agreement.

4.   PAYMENTS

     4.1   In consideration of the rights and licenses granted hereunder, the
Company shall pay or cause to be paid to [ * ] amounts as follows:

           (a)  _________________________________________________________

           (b)  _________________________________________________________

           (c)  _________________________________________________________

           (d)  a royalty of [ * ] of Net Sales of Licensed Products sold by
the Company within the scope of a Valid Claim within the Licensed Patent Rights
in the country they are made or sold.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       4.

<PAGE>

Notwithstanding the above, the royalty due [ * ] on Net Sales of Licensed
Products, the manufacture, use or sale of which would not infringe a Valid
Claim in the country for which they are sold but which are within the scope
of a Pending Claim in such country, shall be fifty percent (50%) of the
royalty due under Section 4.l(d).

     4.2   In the event that a Licensed Product is sold in combination as a
single product with another product whose sale and use are not covered by the
Licensed Patent Rights in the country for which the combination product is
sold, Net Sales from such sales, for purposes of calculating the amounts due
under Section 4.1 above, shall be calculated by multiplying the Net Sales of
that combination by the fraction A/(A + B), where A is the gross selling
price of the Licensed Product, as the case may be, sold separately, and B is
the gross selling price of the other product sold separately. In the event
that no such separate sales are made by the Company, Net Sales for royalty
determination shall be as reasonably allocated by the Company between such
Licensed Product and such other product, based upon their relative importance
and proprietary protection.

     4.3   Licensed Products sold, leased or otherwise distributed by the
Company's sublicensees shall be considered to be sales, leases or disposals
of Licensed Products by the Company for purposes of royalty payments and
reports under this Agreement. The obligation to pay royalties pursuant to
this Agreement is imposed only once with respect to the sale of a particular
Licensed Product regardless of the number of claims or patents that cover
such Licensed Product. The Company shall have no obligation to pay royalties
on Licensed Products used in research and development, in clinical trials or
other noncommercial purposes, or distributed as samples.

     4.4   The Company's obligation to pay royalties hereunder shall continue
on a country-by-country basis until (i) the expiration of the last-to-expire
issued patent within the Licensed Patent Rights in such country, or (ii) [ * ]
following the first commercial sale of a Licensed Product in a country, if no
patent covering such Licensed Product has been issued in such country.
Thereafter, the Company shall have a fully paid up license under Licensed
Patent Rights, Biological Materials and Know-How to make, have made, use,
sell, lease, import, have imported, offer for sale or otherwise exploit the
Licensed Product(s) for any use in that country.

     4.5  _______________________________________________________________

     4.6  _______________________________________________________________

     4.7   Unless this Agreement is terminated earlier, within sixty (60)
days following the first achievement by the Company or a sublicensee of the
following milestones with respect to the first Licensed Product within the
scope of a Valid Claim within the Licensed Patent Rights, the Company shall
pay to [ * ] [ * ] milestone payments as follows:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       5.

<PAGE>

<TABLE>
<CAPTION>

                   EVENT                                        Payment
   --------------------------------------------------           -------
<S>                                                             <C>
   Enrollment of first patient in a Company-sponsored           $ [ * ]
   [ * ] clinical trial of a Licensed Product

   Enrollment of first patient in a Company-sponsored           $ [ * ]
   [ * ] clinical trial of a Licensed Product

   Approval of NDA in U.S. of a Licensed Product                $ [ * ]

</TABLE>

     4.8   Upon commencement of commercial sales of any Licensed Products
which generate a royalty to [ * ] pursuant to this Agreement, the Company
shall within ninety (90) days of the close of the fiscal semi-annual period,
provide semi-annual reports to [ * ] showing the total Net Sales of Licensed
Products sold, leased or otherwise disposed of during such period and the
calculation of royalties thereon. Any royalty then due and payable shall be
included with such report. All reports provided hereunder by the Company
shall be the Confidential Information of the Company, subject to Section 7
herein. The Company's records shall be open to inspection by an independent
certified public accountant designated by [ * ] for three (3) years from the
submission of such reports and payments, subject to execution of a
confidentiality agreement reasonably acceptable to the Company, once per
calendar year at reasonable times, at [ * ]expense, for the sole purpose of
verifying the accuracy of the reports and royalty payments made by the
Company. The accountant shall report to [ * ] only whether there has been an
underpayment and, if so, the amount thereof.

5.   TIMES AND CURRENCIES OF PAYMENT

     5.1   Royalty payments shall be made in United States dollars or if
sales are made in the currency of other countries, royalties shall be
calculated in the currency of such other country and be converted into United
States dollars using the applicable exchange rate for sale of U.S. dollars
listed by the foreign exchange desk of the Bank of America on the last day of
the applicable reporting period.

     5.2   If at any time legal restrictions prevent the prompt remittance of
part or all royalties by the Company with respect to any country where a
Licensed Product is sold, the Company shall have the right and option to make
such payment by depositing the amount thereof in local currency to an account
in the name of [ * ] in a bank or other depository in such country.

6.   SUBLICENSEES

     6.1   The Company and its Affiliates shall have the right to grant and
authorize sublicenses under the Licensed Technology and Improvement Technology
to commercial entities for research purposes and for commercial purposes,
including without limitation, to make, have made, import, have imported, use,
lease, offer for sale and sell Licensed Products in the Territory.

     6.2 The Company shall have the sole discretion to determine the financial
and other terms on which any sublicenses shall be granted under the Licensed
Technology, subject to the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       6.

<PAGE>

provisions herein. Any sublicense(s) granted by the Company under this
Agreement shall be subject and subordinate to the terms and conditions of
this Agreement, except the financial terms of the sublicense(s) may require
greater payments than the financial terms in this Agreement.

     6.3   Notwithstanding Section 2.1 above, [ * ], on behalf of the
Company, may continue to grant limited, non-transferable, research
sublicenses to academic institutions, governmental and other not-for-profit
entities using the form sublicense agreement attached hereto as Exhibit B.
[ * ] shall not enter into or agree to enter into any agreement with such an
entity which deviates in any way from the form agreement set forth in Exhibit
B, without the prior written consent of the Company. [ * ] shall provide the
Company with a copy of each such research license entered by [ * ] promptly
following the execution of such agreement.

     6.4   In the event of any termination of this Agreement, any sublicenses
granted under or this Agreement shall also terminate unless such sublicensees
provide [ * ] written notice that they will abide by the applicable terms of
this Agreement.

     6.5   In no event shall a default or breach of a sublicensee of a
sublicense granted by the Company pursuant to this Agreement constitute by a
default or breach by the Company of this Agreement or be deemed a valid basis
for the termination of this Agreement.

7.   CONFIDENTIAL INFORMATION

     7.1   Each Party and its Affiliates and sublicensees shall treat as
confidential all Confidential Information received from the other Party
hereto, shall not use such Confidential Information except as expressly set
forth herein or otherwise authorized in writing, shall implement reasonable
procedures to prohibit the disclosure, unauthorized duplication, misuse or
removal of such Confidential Information and shall not disclose such
Confidential Information to any third party except as may be necessary and
required in connection with the rights and obligations of such party under
this Agreement, and subject to confidentiality obligations at least as
protective as those set forth herein. Without limiting the foregoing, each of
the parties shall use at least the same procedures and degree of care which
it uses to prevent the disclosure of its own confidential information to
prevent the disclosure of Confidential Information of the other Party. As
used herein, the term "Confidential Information" shall mean any information
expressly designated as Confidential Information in this Agreement and
information disclosed by one Party to another pursuant to this Agreement
which is in written, graphic, machine readable or other tangible form and is
marked "Confidential" to indicate its confidential nature. Confidential
Information may also include oral information disclosed by one Party to
another pursuant to this Agreement, provided that such information is
designated as confidential at the time of disclosure and within thirty (30)
days after its oral disclosure is reduced to a written summary by the
disclosing Party, which summary is marked in a manner to indicate its
confidential nature and delivered to the receiving Party.

     7.2   Notwithstanding the above, neither Party has any obligation of
confidence under this Agreement with respect to any information which:

               (i)    may be demonstrated to have been known to the receiving
Party prior to the time of disclosure thereof by the disclosing Party; or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       7.

<PAGE>

               (ii)   without breach of this Agreement, has been published or
is otherwise available to the public at any time whether before or after the
time of disclosure to such Party; or

               (iii)  is at any time lawfully received by such Party from a
third party who has no obligation of confidence to a Party in respect hereof.

     7.3   Each Party hereto may disclose another's Confidential Information
to the extent such disclosure is reasonably necessary in filing or prosecuting
patent applications, prosecuting or defending litigation, complying with
applicable governmental regulations or otherwise submitting information to tax
or other government authorities, making a permitted sublicense or other
exercise of its rights hereunder or conducting clinical trials, provided that
if a Party is required to make any such disclosure of another Party's secret or
Confidential Information, other than pursuant to a confidentiality agreement,
it will give reasonable advance notice to the latter Party of such disclosure
requirement and, will use its best efforts to secure confidential treatment of
such information prior to its disclosure (whether through protective orders or
otherwise).

8.   REPRESENTATIONS AND WARRANTIES

     8.1   [ * ] represents and warrants that: (i) it is a nonprofit
corporation duly organized, validly existing and in good standing under the
laws of New York (ii) the execution, delivery and performance of this
Agreement have been duly authorized by all necessary action on the part of
[ * ]; (iii) it is the sole and exclusive owner of all right, title and
interest in the Licensed Patent Rights; (iv) the Licensed Patent Rights are
free and clear of any lien, security interest or restriction on transfer or
license; (v) [ * ] has not previously granted, and will not grant during the
term of this Agreement, any right, license or interest in and to the Licensed
Patent Rights, Biological Materials and Know-How, or any portion thereof, in
conflict with the rights, exclusive license and interest granted to the
Company herein; (vi) it has complied fully with all requirements of 35 U.S.C.
Section 201 et seq. and all implementing regulations with respect to perfecting
its interest in the Licensed Patent Rights; (vii) Exhibit A contains a complete
and accurate listing of all Licensed Patent Rights existing as of the Effective
Date; and (viii) there are no actions, suits, investigations, claims or
proceedings pending in any way relating to the Licensed Patent Rights,
Biological Materials or Know-How.

     8.2   The Company represents and warrants that: (i) it is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Delaware; and (ii) the execution, delivery and performance of this
Agreement have been duly authorized by all necessary corporate action on the
part of the Company.

     8.3   [ * ] EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS WARRANTIES
AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
ANY PARTICULAR PURPOSE OF BIOLOGICAL MATERIALS, LICENSED PROCESSES OR LICENSED
PRODUCTS CONTEMPLATED BY THIS AGREEMENT. FURTHER, [ * ] HAS MADE NO FORMAL
INVESTIGATION AND THEREORE CAN MAKE NO REPRESENTATION THAT BIOLOGICAL MATERIALS
SUPPLIED BY IT OR THE METHODS USED IN MAKING OR

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       8.

<PAGE>

USING SUCH MATERIALS ARE NOW OR WILL REMAIN FREE FROM LIABILITY FOR PATENT
INFRINGEMENT.

9.   _____________________________________

     9.1   _____________________________________________________________

     9.2   _____________________________________________________________

10.  PUBLICITY

The Company will not use either directly or by implication the name of [ * ],
or the name of any member of the faculty or staff thereof for any commercial
or promotional purposes without prior notification and written agreement of
[ * ]. Except as expressly provided herein, the Parties agree not to disclose
the terms of this Agreement to any third party without the prior written
consent of the other Party to the fact and form of such disclosure, except as
required by securities or other applicable laws, to prospective investors and
to such party's accountants, attorneys and other professional advisors.
Notwithstanding the above, the Company may disclose the existence of this
Agreement and issue a press release, reasonably acceptable to [ * ], describing
this Agreement and the rights granted the Company by [ * ] under this
Agreement, and disclose to actual and potential sublicensees the rights granted
the Company by [ * ] under this Agreement.

11.  PATENTS

     11.1   Except as set forth in Section 11.4, the Company shall have the
sole right to control the preparation, filing, prosecution and maintenance of
the Licensed Patent Rights, and any interference or opposition proceeding
relating thereto, using patent counsel of its choice. The Company shall consult
with [ * ] regarding the prosecution of any such patent applications, by
providing [ * ]a reasonable opportunity to review and comment on all proposed
submissions to any patent office before submittal, and provided further that
the Company shall keep [ * ] reasonably informed as to the status of such
patent applications by promptly providing [ * ] copies of all communications
relating to such patent applications that are received from any patent office.
If the Company informs [ * ] in writing that the Company no longer wishes to
conduct such activities with regard to any such patent applications or patents
in any country, then [ * ]will be free, at its discretion and expense to either
abandon the subject patent applications or to continue such activities, and the
Company shall have no further rights with respect to the applicable patent
applications or patents in such countries.

     11.2  During the term of the Agreement, the Company shall be responsible
for one hundred percent (100%) of the expenses incurred in connection with the
activities set forth in Section 11.1. above. _________________________________
With respect to patent-related costs incurred after the Effective Date, the
Company shall reimburse [ * ] within thirty (30) days following invoice for
such costs, in a form reasonably acceptable to the Company.

     11.3  If either Party hereto becomes aware that any Licensed Patent Rights
are being or have been infringed by any third party, such Party shall promptly
notify the other Party hereto in

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       9.

<PAGE>

writing describing the facts relating thereto in reasonable detail. The
Company shall have the initial right, but not the obligation, to institute,
prosecute and control any action, suit or proceeding (an "Action") with
respect to such infringement, including any declaratory judgment action, at
its expense, using counsel of its choice; provided, however, during the
pendency of any such Action, the Company shall be entitled to place any
royalties otherwise due [ * ]hereunder in a separate account controlled by
the Company. If the pertinent Licensed Patent Rights are found invalid or
unenforceable in such an Action, or any appeal thereof, the Company may retain
the amounts placed in such account without further obligation to [ * ] with
regard thereto. If the Licensed Patent Rights are not held invalid or
unenforceable in such an Action, or any appeal thereof, the Company shall
promptly pay the amounts deposited in such account to [ * ]. Any amounts
recovered from third parties in any such Action shall be retained by the
Company. In the event the Company fails to initiate or defend any Action
involving the Licensed Patent Rights within one (1) year of receiving notice
of any commercially significant infringement, [ * ] shall have the right, but
not the obligation, to initiate and control such an Action, and the Company
shall cooperate reasonably with [ * ], at [ * ]'s request, in connection with
any such Action. Any amounts recovered in such Action shall be used first to
reimburse the Company and [ * ] for the expenses incurred in connection with
such Action, and any remainder retained by [ * ].

     11.4  In the event the parties believe an interference may be declared
or an interference is declared between any patent application or patent
within the Licensed Patent Rights and any patent application or patent owned
or controlled by the Company relating to the production of high titer
retroviruses, the parties agree to amicably settle any such prospective or
actual interference in accordance with the procedure set forth on Exhibit C.
The Company shall have the exclusive right to initiate such settlement
procedure after consultation with [ * ]. In the event of any such prospective
or actual interference and the settlement thereof, each Party shall pay its
own costs associated therewith and the parties shall equally share the costs
of any arbitration, including without limitation, administration and
arbitrator fees. It is understood and agreed that in the event an
interference is declared, neither Patty shall have an obligation to
participate in such a proceeding, but each hereby acknowledges that it
understands that a failure to participate may result in an adverse outcome
which could have a material adverse impact on such Party. It is further
understood and agreed that any patent applications and patents within the
Licensed Patent Rights which are involved in any interference shall remain
subject to the license granted the Company herein.

12.  LICENSED PRODUCT LIABILITY

The Company agrees to indemnify, defend and hold harmless [ * ] and its
trustees, officers, agents, faculty, employees, and students (the
"Indemnitees"), from any and all liability arising from injury or damage to
persons or property resulting directly or indirectly from the Company's
acquisition, use, manufacture, sublicense or sale of any Licensed Product
covered by Licensed Patent Rights or Know-How licensed hereunder.
Notwithstanding the foregoing, the Company expressly retains any and all
claims it may have against Indemnitees arising from indemnitees' negligence
or willful misconduct. The Company's obligation to indemnify the Indemnitees
under this Section 11 shall not apply unless the indemnified Party promptly
notifies the Company of any claim or liability subject to this Section 12 and
cooperates fully with the Company in the defense of any such claim or
proceeding. The Company further agrees to obtain, prior to the first

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      10.

<PAGE>

commercial sale of a Licensed Product, and maintain in force for at least
fifteen (15) years following the last sale of a Licensed Product, product
liability insurance coverage of at least [ * ] dollars or a lesser amount as
appropriate to the risk as determined by reference to reliable standards in
the industry, such insurance to specifically name [ * ] as an additional
insured.

13.  NOTICES

Any notice required to be given pursuant to this Agreement shall be in writing
and may be made by personal delivery or by registered or certified mail, return
receipt requested, by one Party to the other Party at the addresses noted below:

         In the case of the Company, notice should be sent to:

         Cell Genesys, Inc.
         322 Lakeside Drive
         Foster City, California 94404
         Attn: Senior Vice President, Corporate Development

         In the case of [ * ], notice should be sent to:

         [ * ]
         Attn: Office of the General Counsel

14.  LAW TO GOVERN

This Agreement shall be interpreted and governed in accordance with the laws of
the State of New York.

15.  ASSIGNMENT

This Agreement may not be assigned by either Party without the prior written
consent of the other; PROVIDED, HOWEVER, the Company may assign this Agreement
in connection with the transfer of all or substantially all of its business
relating to the subject matter of this Agreement whether by sale, merger,
operation of law or otherwise.

16.  TERMINATION

     16.1  The Company shall have the right to terminate this Agreement at
any time with respect to any Licensed Patent Right or any country upon ninety
(90) days prior written notice to [ * ]. Such termination shall automatically
terminate the license rights provided in Section 2 with respect to such
Licensed Patent Rights hereof in such country but shall not relieve the
Company of the obligation to pay royalties for any period prior to the
effective date of termination.

     16.2  Either Party may terminate this Agreement in the event of a
material breach by the other Party which is not cured within a reasonable
time, provided only that the offending Party is given notice of the breach
and not less than ninety (90) days in which to cure such breach.

     16.3  Sections 2.4, 6.4 and 24.3 and Articles 7, 8, 10, 12, 14, 17 and
25 shall survive expiration or termination of this Agreement for any reason.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      11.

<PAGE>

17.  RESOLUTION OF DISPUTES

The Parties agree that in the event of it dispute between them arising from,
concerning, or in any way relating to this Agreement, the Parties shall
undertake good faith efforts to resolve the same amicably between themselves.

18.  FORCE MAJEURE

The Parties shall not be liable in any manner for failure or delay in
fulfillment of all or part of this Agreement, directly or indirectly caused
by acts of God, governmental orders or restrictions, war, war-like
conditions, revolution, riot, looting, strike, lockout, fire, earthquake,
flood or other similar or dissimilar cause or circumstances beyond the
nonperforming Party's control. The nonperforming Party shall promptly notify
the other Party of the cause or circumstance and shall recommence its
performance of its obligations as soon as practicable after the cause or
circumstance ceases.

19.  BINDING UPON SUCCESSORS AND ASSIGNS

Subject to the limitations on assignment herein, this Agreement shall be
binding upon and inure to the benefit of successors in interest or assigns of
[ * ] and the Company. Any such successor or assignee of a Party's interest
shall expressly assume in writing the performance of all the terms and
conditions of this Agreement to be performed by said Party.

20.  INDEPENDENT CONTRACTORS

The relationship between [ * ] and the Company is that of independent
contractors. [ * ] and the Company are not joint venturers, partners,
principal and agent, master and servant, employer or employee, and have no
other relationship other than independent contracting parties. [ * ] shall
have no power to bind or obligate the Company in any manner, other than as is
expressly set forth in this Agreement. Likewise, the Company shall have no
power to bind or obligate [ * ] in any manner, other than as is expressly set
forth in this Agreement.

21.  SEVERABILITY

If any provision of this Agreement is ultimately held to be invalid, illegal
or unenforceable, the validity, legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby.

22.  NO WAIVER

Any delay in enforcing a Party's rights under this Agreement or any waiver as
to a particular default or other matter shall not constitute a waiver of such
Party's rights to the future enforcement of its rights under this Agreement,
excepting only as to an express written and signed waiver as to a particular
matter for a particular period of time.

23.  NO IMPLIED OBLIGATIONS

It is understood and agreed that nothing in this Agreement shall be deemed to
prevent the Company from commercializing technology or products similar to or
competitive with the Licensed Technology or the Licensed Products. Nor shall
anything in this Agreement impair the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      12.

<PAGE>

right of the Company to independently acquire, license, develop or have
others develop for it technology performing similar or equivalent functions
as the Licensed Technology, or to develop, market or distribute products
based on such technology in addition to or in lieu of the Licensed Products.

24.  COMPLIANCE WITH LAWS. REGULATIONS AND STANDARDS

     24.1  The Company recognizes that the use of Biological Materials
carries with it certain safety risks to both the environment and the
population that are inherent in such materials, and shall exercise prudent
scientific laboratory procedures in the use of said Biological Materials.

     24.2  The inventors and [ * ] recognize and have advised that the
Biological Materials may be used to create infectious retroviruses with a
broad host range, that the supplied materials may be used to create
retroviruses that can infect human cells in both vitro and in vivo, that the
Biological Materials and all materials derived thereof should be handled and
used with all due care in accordance with generally acceptable scientific
guidelines establishing appropriate precautions and approved by the
Institutional Biosafety Committee or similar authority at the Company.

     24.3  The Company shall bear all risk to the Company and/or to any
others resulting from use, directly or indirectly, to which the Company puts
the Biological Materials or any progeny or cells or cell lines derived from
it.

25.  NO CONSEQUENTIAL DAMAGES

IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR SPECIAL, INCIDENTAL OR
CONSEQUENTIAL DAMAGES ARISING OUT OF ANY BREACH OF THIS AGREEMENT.

26.  ENTIRE UNDERSTANDING

This Agreement with its Exhibits represents the entire understanding between
the Parties with respect to the subject matter hereof and supersedes any other
agreement, expressed or implied, by the Parties with respect to the Licensed
Patent Rights, Biological Materials, Know-How and Improvement Technology, and
supersedes and merges all prior negotiations, discussions and agreements,
including without limitation, the Prior Agreement between the parties. This
Agreement may not be amended or modified except in a written document signed
by authorized representatives of the Parties.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly
executed as of the day and year first above written.

                                       CELL GENESYS, INC.

                                       By:  /s/ R. Scott Greer
                                          ------------------------------------
                                       Title: Senior Vice President
                                              Corporate Development

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      13.

<PAGE>

                                       Date: February 2. 1996

                                       [ * ]

                                       By:   [ * ]
                                          --------------------------------------

                                       Title: Vice President and General Counsel
                                              January 31, 1996

                                       Date:  January 31, 1996

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      14.

<PAGE>

                                   EXHIBIT "A"

                             LICENSED PATENT RIGHTS

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      1.
<PAGE>

                    AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

This Amendment to Exclusive License Agreement ("Amendment"), effective as of
November 3, 1998, by and between Cell Genesys, Inc.,("Company"), a
corporation organized and existing under the laws of the State of Delaware,
having an office at 342 Lakeside Drive, Foster City, California 94404, and
[ * ] ("[ * ]"), a nonprofit education corporation organized and existing
under the laws of the State of New York, having an office at [ * ] (Company
and [ * ] collectively, the "Parties").

                                   BACKGROUND

The Parties desire to amend that certain Exclusive License Agreement by and
between Company and [ * ] effective as of January 31, 1996 (the "Agreement")
as set forth herein below.

         NOW, THEREFORE, the Parties agree as follows:

1.       AMENDMENT. This Amendment hereby amends the Agreement to incorporate
         the terms and conditions set forth in this Amendment. The relationship
         of the Parties shall continue to be governed by the terms and
         conditions of the Agreement, as amended herein; and in the event that
         there is any conflict between the terms and conditions of the Agreement
         and this Amendment, the terms and conditions of this Amendment shall
         control. As used in this Amendment, all capitalized terms shall have
         the meanings defined for such terms in this Amendment or, if not
         defined in the Amendment, the meanings defined in the Agreement.

2.       MODIFICATION TO THE AGREEMENT.

         2.1   Section 4.6 of the Agreement is hereby amended to read in its
         entirety as follows:

         "4.6  COMMERCIAL SUBLICENSES. It is understood and agreed that
         Company shall have the right, at its sole discretion, to grant
         Commercial Sublicenses to third parties ____________________________.
         As used herein, "Commercial Sublicense" shall mean Commercial Target
         Sublicenses and any other sublicense right granted under the Licensed
         Technology, provided, however, Commercial Sublicenses shall exclude
         rights granted by Company to a third party pursuant to an agreement
         substantially in the form of Exhibit D to this Agreement (i.e.,
         research sublicenses)."

         2.2   The Agreement is hereby amended to add the following new
         Section 4.9:

         "4.9  COMMERCIAL TARGET SUBLICENSES. Subject to the terms and
         conditions set forth in this Section 4.9 below and without limiting
         the provisions of Section 4.6 above or Article 6 below, Company shall
         have the right to grant and authorize Commercial Target Sublicenses
         to third parties (each such third party, a "Commercial Target
         Sublicensee") on terms and conditions as Company deems appropriate in
         its sole discretion.

         (a)   MILESTONE AND MAINTENANCE FEES. In addition to amounts payable

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      1.

<PAGE>

         pursuant to Section 4.3 above and in consideration of Company's right
         to grant and authorize Commercial Target Sublicenses pursuant to this
         Section 4.9 ________________________________________. Payments due
         under this Section 4.9(a) shall be due and payable within sixty (60)
         days after the calendar quarter in which the Milestone Fee
         or Maintenance Fee, as applicable, is received by Company
         ___________________________________________.

                  (b)  TERMS. For purposes of this Section 4.9 the following
         capitalized terms shall have the following meanings. "Commercial Target
         Sublicense" shall mean a sublicense under the Licensed Technology that
         includes the right to conduct Target Validation using the Licensed
         Technology. "Target Validation" shall mean the process by which the
         function of nucleotide sequences are identified, determined and/or
         confirmed; and/or the function of nucleotide sequences are identified,
         determined and/or confirmed as being significant in a disease or other
         biological pathway in which pharmacological or other intervention is
         sought to affect the function of that pathway.
         ___________________________________________________________________.

                  (c)  SURVIVAL. Subject to Section 6.4 below, Commercial
         Sublicenses, including Commercial Target Sublicenses, shall survive the
         termination of this Agreement, provided that the Commercial Sublicensee
         or Commercial Target Sublicensee, as the case may be, agrees to be
         bound by the applicable terms and conditions of this Agreement."

3.       ENTIRE AGREEMENT. Together the Agreement (including the Exhibits
         thereto) and this Amendment constitute the entire agreement between the
         Parties in connection with the subject matter thereof and supersede all
         prior and contemporaneous agreements, understandings, negotiations and
         discussions, whether oral or written, of the Parties.

         IN WITNESS WHEREOF, the Parties have executed this Amendment.

CELL GENESYS, INC.                           [ * ]

By: /s/ Bruce A. Hironaka                    By:  [ * ]
   ---------------------------------            ------------------------------

Title:  Vice President, Corp. Devel.         Title:  Vice President and
                                                     General Counsel
      ------------------------------               ---------------------------

Date:  November 16, 1998                     Date:  11/3/98
     -------------------------------              ----------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       2.

<PAGE>

                                   APPENDIX B

                                 [ * ] CELL LINE

                                     [ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       3.

<PAGE>

                                   APPENDIX C

                           RIGEL BIOLOGICAL MATERIALS

[ * ] Vectors:

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       4.

<PAGE>

                                   APPENDIX D

                       NOLAN AND NOLAN/ROTHENBERG PATENTS

U.S. Patent Application No. 08/589,109, entitled "Methods for Screening for
Transdominant Effector Peptides and RNA Molecules"  (the Nolan/Rothenberg
Patent Application).

U.S. Patent Applications Nos. 08/789,333, 08/589,911 and 08/963,368, entitled,
"Methods for Screening for Transdominant Intracellular Effector Peptides and
RNA Molecules"  (the Nolan Patent Application).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       5.

<PAGE>

                                    APPENDIX E

                                LICENSE AGREEMENT

                                 BY AND BETWEEN

         THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

                                       AND

                           RIGEL PHARMACEUTICALS, INC.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       1.

<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                               PAGE
<S>                                                                                            <C>
1.    DEFINITIONS. ...............................................................................1

2.    LICENSED RIGHTS.............................................................................3

3.    TRANSFER OF BIOLOGICAL MATERIALS AND KNOW-HOW...............................................4

4.    PAYMENTS....................................................................................4

5.    TIMES AND CURRENCIES OF PAYMENT.............................................................6

6.    SUBLICENSEES ...............................................................................6

7.    CONFIDENTIAL INFORMATION....................................................................7

8.    REPRESENTATIONS AND WARRANTIES..............................................................8

9.    ______________________________..............................................................9

10.   PUBLICITY...................................................................................9

11.   PATENTS.....................................................................................9

12.   LICENSED PRODUCT LIABILITY.................................................................10

13.   NOTICES....................................................................................11

14.   LAW TO GOVERN..............................................................................11

15.   ASSIGNMENT.................................................................................11

16.   TERMINATION................................................................................11

17.   RESOLUTION OF DISPUTES.....................................................................12

18.   FORCE MAJEURE..............................................................................12

19.   BINDING UPON SUCCESSORS AND ASSIGNS........................................................12

20.   INDEPENDENT CONTRACTORS....................................................................12

21.   SEVERABILITY...............................................................................12

22.   NO WAIVER..................................................................................12

23.   NO IMPLIED OBLIGATIONS.....................................................................13

24.   COMPLIANCE WITH LAWS. REGULATIONS AND STANDARDS............................................13

25.   NO CONSEQUENTIAL DAMAGES...................................................................13

26.   ENTIRE UNDERSTANDING.......................................................................13

APPENDIX E  LICENSE AGREEMENT.....................................................................1

1.    DEFINITIONS.................................................................................1

2.    GRANT; TRANSFER OF LICENSED BIOLOGICAL MATERIALS............................................2
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       i.
<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                                              PAGE
<S>                                                                                           <C>
3.   LICENSE ROYALTIES...........................................................................2

4.   PATENTS; NEW INVENTIONS.....................................................................3

5.   WARRANTIES..................................................................................3

6.   INDEMNITY...................................................................................4

7.   STANFORD NAMES AND MARKS....................................................................5

8.   SUBLICENSE(S)...............................................................................5

9.   TERM AND TERMINATION........................................................................5

10.  ASSIGNMENT..................................................................................6

11.  ARBITRATION.................................................................................6

12.  NOTICES.....................................................................................7

13.  WAIVER......................................................................................7

14.  APPLICABLE LAW..............................................................................7

15.  DISCLAIMER OF AGENCY........................................................................7

16.  SEVERABILITY................................................................................8

17.  ENTIRE AGREEMENT............................................................................8

18.  COUNTERPARTS................................................................................8
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       ii.

<PAGE>

                                   APPENDIX E

                                LICENSE AGREEMENT

     Effective as of June 1, 1999 (the "Effective Date"), THE BOARD OF
TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, a body having corporate
powers under the laws of the State of California ("STANFORD") and RIGEL
PHARMACEUTICALS, INC., a Delaware corporation having a principle place of
business at 240 East Grand Avenue, South San Francisco, CA 94080 ("RIGEL"),
agree as follows:

                                    RECITALS

     A.   STANFORD owns certain [ * ] cell lines and derivatives thereof and
biological components related thereto.

     B.   RIGEL desires to obtain a non-exclusive license to such materials for
use in the Field, with the right to grant one non-exclusive sublicense to Cell
Genesys, Inc.

1.   DEFINITIONS.

     1.1   "CELL GENESYS" means Cell Genesys, Inc., a Delaware corporation,
having a principal place of business at 342 Lakeside Drive, Foster City,
CA 94404.

     1.2   "FIELD" means any and all fields of use, including, without
limitation, any research or commercial field of use.

     1.3   "LICENSED BIOLOGICAL MATERIALS" means the materials listed on
Exhibit A.

     1.4   "LICENSED KNOW-HOW" means:

           (a)  any and all tangible or intangible know-how, trade secrets,
inventions (whether or not patentable), processes, data, and other information
owned by STANFORD as of the Effective Date that are necessary or useful for
the use of the Licensed Biological Materials; and

           (b)  any modifications or progeny of the information and materials
in subsection (a) above that STANFORD may elect to provide to RIGEL at
STANFORD's sole and exclusive discretion.

     1.5   "PATENT" shall mean all foreign and domestic patents (including,
without limitation, extensions, reexaminations, reissues, renewals and
inventors certificates) and patents issuing from patent applications (including
substitutions, provisionals, divisionals, continuations and continuations-in-
part).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       1.

<PAGE>

2.   GRANT; TRANSFER OF LICENSED BIOLOGICAL MATERIALS.

     2.1   STANFORD hereby grants, and RIGEL hereby accepts, a worldwide,
non-exclusive license (without the right to sublicense except to Cell Genesys
in the field of human and/or animal gene therapy as provided in Article 8)
under STANFORD's right, title and interest in the Licensed Biological
Materials to conduct research and development and to use the Licensed
Biological Materials to make, have made, use, import, offer for sale and sell
products in the Field.

     2.2   STANFORD hereby grants, and RIGEL hereby accepts, a worldwide,
non-exclusive license (without the right to sublicense except to Cell Genesys
in the field of human and/or animal gene therapy as provided in Article 8)
under STANFORD's right, title and interest in the Licensed Know-How to use
the Licensed Know-How in the Field.

     2.3   STANFORD shall have the right to use the Licensed Know-How and the
Licensed Biological Materials for its own bona fide research, including
sponsored research and collaborations. In addition, STANFORD shall have the
right to distribute the Licensed Biological Materials.

     2.4   Promptly after the Effective Date, STANFORD shall transfer to
RIGEL such quantities of the Licensed Biological Materials as RIGEL shall
reasonably request. Thereafter, STANFORD shall transfer to RIGEL such
additional quantities of Licensed Biological Materials as RIGEL shall
reasonably request in the event that RIGEL's stock of the Licensed Biological
Materials is destroyed or contaminated.

3.   LICENSE ROYALTIES.

     3.1   In partial consideration for the license granted by STANFORD to
RIGEL under Section 2.1, RIGEL agrees to pay to STANFORD the following:

           (a)  An initial, nonrefundable license issue royalty of [ * ],
which amount shall be paid within thirty (30) days after the Effective Date.

           (b)  A royalty payment equal to [ * ] on each of the first three
(3) anniversaries of the Effective Date.

     After the third (3rd) anniversary of the Effective Date, the sublicense
shall be considered perpetual and fully paid-up.

     3.2   If RIGEL grants to Cell Genesys a sublicense under the Licensed
Biological Materials to use and sell products in the field of human and/or
animal gene therapy, RIGEL shall pay to STANFORD during the term of such
sublicense a sublicense fee as follows:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       2.

<PAGE>

       Upon signing of the sublicense                            $[ * ]

       On each of the first three (3) anniversaries of           $[ * ]
       the effective date of such sublicense

       On the 4th, 5th and 6th anniversaries of the              $[ * ]
       effective date of such sublicense

After the sixth (6th) anniversary of the effective date of such sublicense,
the sublicense shall be considered perpetual and fully paid-up.

4.   PATENTS; NEW INVENTIONS.

     Subject to the terms and conditions of this Agreement, any patentable
inventions or discoveries conceived or reduced to practice by the employees,
agents or consultants of one party during the course of the Agreement ("Sole
Inventions") shall be the property of such party. Any patentable inventions
or discoveries conceived or reduced to practice jointly by employees, agents
or consultants of STANFORD and RIGEL as determined in accordance with United
States rules of inventorship ("Joint Inventions") during the course of and
pursuant to this Agreement shall be owned jointly by STANFORD and RIGEL, each
to own an undivided one-half (1/2) interest in such Joint Invention. Each
party shall cooperate with the other in completing any patent applications
relating to Joint Inventions, and in executing and delivering any instrument
required to assign, convey or transfer to such other party its undivided
one-half (1/2) interest.

5.   WARRANTIES.

     5.1   STANFORD's Office of Technology Licensing represents and warrants
that to the best of its knowledge as of the Effective Date, STANFORD has not
sought or obtained patent protection of the Licensed Biological Materials or
any use thereof in the Field.

     5.2   STANFORD's Office of Technology Licensing represents and warrants
that as of the Effective Date, it has no knowledge of claims by third parties
that the use of the Licensed Biological Materials infringes any patents,
copyrights or other rights of third parties.

     5.3   STANFORD represents and warrants that it has all right, power and
authority necessary to grant the licenses set forth in Article 2 to RIGEL.

     5.4   RIGEL agrees that nothing in this Agreement grants RIGEL any express
or implied license or right under or to:

           (a)  U.S. Patent 4,656,134, entitled "Amplification of Eucaryotic
Genes" or any patent application corresponding thereto; or

           (b)  U.S. Patent 5,070,012, entitled "Monitoring of Cells and
Trans-Activating Transcription Elements" or any patent application corresponding
thereto; or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       3.

<PAGE>

           (c)  U.S. Patent 5,804,387, entitled "FACS-Optimized Mutants of
the Green Fluorescent Protein (GFP) or any patent application corresponding
thereto.

     5.5   STANFORD agrees that nothing in this Agreement grants STANFORD any
express or implied license or right under or to U.S. Patent Application Nos.
08/789,333, 08/589,911, or 08/963,368, entitled "Method for Screening for
Transdominant Intracellular Effector Peptides and RNA Molecules," or any
continuations, divisionals or continuation-in-parts thereof or any patents
which may issue therefrom.

     5.6   Except as provided in Sections 5.1, 5.2 and 5.3 and as otherwise
expressly set forth in this Agreement, nothing in this Agreement will be
construed as a warranty or representation that anything made, used, sold, or
otherwise disposed of under any license granted in this Agreement is or will
be free from infringement of patents, copyrights, and trademarks of third
parties; conferring rights to use in advertising, publicity, or otherwise any
trademark or the name of "STANFORD"; or granting by implication, estoppel, or
otherwise any licenses or rights under patents of STANFORD.

     5.7   EXCEPT AS EXPRESSLY SET FORTH IN THE AGREEMENT, STANFORD MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE LICENSED BIOLOGICAL
MATERIALS OR LICENSED KNOW-HOW WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
TRADEMARK, OR OTHER RIGHTS, OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES.

6.   INDEMNITY.

     6.1   RIGEL agrees to indemnify, hold harmless, and defend STANFORD,
UCSF-Stanford Health Care and Stanford Health Services and their respective
trustees, officers, employees, students, and agents against any and all claims
by third parties for death, illness, personal injury, property damage, and
improper business practices arising out of the manufacture, use, sale, or other
disposition of the Licensed Biological Materials or any products arising or
derived from Licensed Biological Materials, by RIGEL or RIGEL's sublicensee(s)
or customers.

     6.2   STANFORD shall not be liable for any indirect, special,
consequential or other damages whatsoever, whether grounded in tort
(including negligence), strict liability, contract or otherwise. STANFORD
shall not have any responsibilities or liabilities whatsoever with respect to
products arising or derived from Licensed Biological Materials by RIGEL.

     6.3   RIGEL shall at all times comply, through insurance or
self-insurance, with all statutory workers' compensation and employers'
liability requirements covering any and all employees with respect to
activities performed under this Agreement.

     6.4   In addition to the foregoing, RIGEL shall maintain Comprehensive
General Liability Insurance, including Products Liability Insurance, with
reputable and financially secure

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       4.

<PAGE>

insurance carrier(s) to cover the activities of RIGEL and its sublicensee(s)
in the amounts and during the periods specified herein. Such insurance shall
provide minimum limits of liability of One Million Dollars ($1,000,000) as of
the first anniversary of the date upon which RIGEL first leases a facility in
which it will conduct research and development activities, and of Five
Million Dollars ($5,000,000) as of the commencement of human clinical trials.
Such insurance shall include STANFORD, UCSF-Stanford Health Care and Stanford
Health Services, their trustees, directors, officers, employees, students,
and agents as additional insureds. Such insurance shall be written to cover
claims incurred, discovered, manifested or made during or after the expiration
of this Agreement. At STANFORD's request, RIGEL shall furnish a Certificate of
Insurance evidencing primary coverage and requiring thirty (30) days prior
written notice of cancellation or material change to STANFORD. RIGEL shall
advise STANFORD, in writing, that it maintains excess liability coverage
(following form) over primary insurance for at least the minimum limits set
forth above. All such insurance of RIGEL shall be primary coverage; insurance
of STANFORD, UCSF-Stanford Health Care or Stanford Health Services shall be
excess and noncontributory.

7.   STANFORD NAMES AND MARKS.

     RIGEL agrees not to identify STANFORD in any promotional advertising or
other promotional materials to be disseminated to the pubic or any portion
thereof or to use the name of any STANFORD faculty member, employee, or student
or any trademark, service mark, trade name, or symbol of STANFORD, UCSF-Stanford
Health Care or Stanford Health Services, or that is associated with any of them,
without STANFORD's prior written consent, except as required by law. STANFORD
shall not unreasonably withhold consent under this Section 7.

8.   SUBLICENSE(S).

     8.1   Subject to the provisions of this Article 8, RIGEL may grant a
sublicense to the license rights granted to RIGEL by STANFORD in Sections 2.1
and 2.2 to Cell Genesys solely in the field of human and/or animal gene therapy.

     8.2   Any sublicense granted by RIGEL to Cell Genesys under this Agreement
shall be subject and subordinate to terms and conditions of this Agreement,
except:

           (a)  Sublicense terms and conditions shall reflect that any
sublicensee(s) shall not grant a sublicense to a third party; and

           (b)  The financial obligations of any sublicensee to RIGEL specified
in the sublicense(s) may be different from those obligations set forth in this
Agreement.

           Any such sublicense(s) also shall expressly include the provisions of
Articles 5 and 6 for the benefit of STANFORD and shall survive any termination
of this Agreement.

     8.3   RIGEL agrees to provide STANFORD with a copy (with financial terms
redacted) of any sublicense granted to Cell Genesys pursuant to this Article
8 and written notice

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       5.

<PAGE>

of the effective date of any termination of such sublicense prior to the
expiration of the Term (as defined in Section 9.1).

9.   TERM AND TERMINATION.

     9.1   The term of this Agreement shall commence upon the Effective Date
and shall expire upon the later of: (a) the expiration of the last to expire
of any Patents owned by STANFORD at any time which claim inventions in the
Licensed Biological Materials or the Licensed Know-How; or (b) twenty (20)
years from the Effective Date (the "Term"). In addition, RIGEL may terminate
this Agreement prior to the expiration of the Term by giving STANFORD notice
in writing at least thirty (30) days in advance of the effective termination
date selected by RIGEL.

     9.2   Either party may terminate this Agreement prior to the expiration
of the Term if the other party is in material breach of any provision hereof
and fails to remedy any such default or breach within thirty (30) days after
written notice thereof to the breaching party.

     9.3   Surviving the expiration of the Term are:

           (a)  Any cause of action or claim of RIGEL or STANFORD, accrued or
to accrue, because of any breach or default by the other party prior to the
expiration of the Term; and

           (b)  Articles 4, 5, 6, 7 and 11; and

           (c)  Article 8 and Sections 2.1 and 2.2; and the licenses granted
thereunder shall be deemed perpetual and fully paid-up.

     9.4   Surviving any termination of this Agreement are:

           (a)  Any cause of action or claim of RIGEL or STANFORD, accrued or
to accrue, because of any breach or default by the other party prior to the
termination of this Agreement; and

           (b)  Articles 4, 5, 6, 7, 8 and 11 and Section 3.2; and

           (c)  Sections 2.1 and 2.2 if RIGEL has fulfilled all of its payment
obligations to STANFORD under Section 3.1 prior to such termination; and the
licenses granted thereunder shall be deemed perpetual and fully paid-up.

10.  ASSIGNMENT.

     This Agreement may not be assigned by either party without the express
written consent of the other party, except that RIGEL may assign the Agreement
in connection with a merger, consolidation or sale of all or substantially all
of RIGEL's assets.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       6.

<PAGE>

11.  ARBITRATION.

     11.1  Any controversy arising under or related to this Agreement, and
any disputed claim by either party against the other under this Agreement
excluding any dispute relating to patent validity or infringement arising
under this Agreement, shall be settled by arbitration in accordance with the
Licensing Agreement Arbitration Rules of the American Arbitration Association.

     11.2  Upon request by either party, arbitration will be by a third party
arbitrator mutually agreed upon in writing by RIGEL and STANFORD within thirty
(30) days of such arbitration request. Judgment upon the award rendered by the
arbitrator shall be final and nonappealable and may be entered in any court
having jurisdiction thereof.

     11.3  The parties shall be entitled to discovery in like manner as if the
arbitration were a civil suit in the California Superior Court.

     11.4  Any arbitration shall be held at Stanford, California, unless the
parties hereto mutually agree in writing to another place.

12.  NOTICES.

     All notices under this Agreement shall be deemed to have been fully given
when done in writing and deposited in the United States mail registered or
certified, and addressed as follows:

     To STANFORD:               Office of Technology Licensing
                                Stanford University
                                900 Welch Road, Suite 350
                                Palo Alto, CA 94304-1850
                                Attention:  Director

     To RIGEL:                  Rigel Pharmaceuticals, Inc.
                                240 East Grand Ave.
                                South San Francisco, CA 94080
                                Attention:  President

Either party may change its address upon written notice to the other party.

13.  WAIVER.

     None of the terms of this Agreement can be waived except by the written
consent of the party waiving compliance.

14.  APPLICABLE LAW.

     This Agreement shall be governed by the laws of the State of California
applicable to agreements negotiated, executed and performed wholly within
California. Any claim or controversy arising out of or related to this
Agreement or any breach hereof shall be submitted to a court of applicable
jurisdiction in the State of California, and each party hereby consents to
the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       7.

<PAGE>

jurisdiction and venue of such court.

15.  DISCLAIMER OF AGENCY.

     Neither party is, or will be deemed to be, the legal representative or
agent of the other, nor shall either party have the right or authority to
assume, create, or incur any third party liability or obligation of any kind,
express or implied, against or in the name of or on behalf of another except
as expressly set forth in this Agreement.

16.  SEVERABILITY.

     If any provision or provisions of this Agreement shall be held to be
invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions shall not be in any way affected or impaired
thereby.

17.  ENTIRE AGREEMENT.

     This Agreement, together with the Exhibit attached hereto, embodies the
entire understanding of the parties and shall supersede all previous
communications, representations or understandings, either oral or written,
between the parties relating to the subject matter hereof. No amendment or
modification hereof shall be valid or binding upon the parties unless made in
writing and signed by duly authorized representatives of both parties.

18. COUNTERPARTS.

         This Agreement may be executed in counterparts, with the same force
and effect as if the parties had executed the same instrument.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement in
duplicate originals by their duly authorized officers or representatives.

THE BOARD OF TRUSTEES OF THE                RIGEL PHARMACEUTICALS, INC.
LELAND STANFORD JUNIOR UNIVERSITY

By:  /s/ Katherine Ku                     By:  /s/ Donald W. Perryman
   ------------------------------------      ---------------------------------
Name:      Katherine Ku                   Name:    Donald W. Perryman
     ----------------------------------        -------------------------------
                                                   VP, Business Development
Title:  Director, Technology Licensing    Title:           June 1999
      ---------------------------------         ------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       8.

<PAGE>

                                    EXHIBIT A

                          LICENSED BIOLOGICAL MATERIALS

[ * ] Vectors:

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.<PAGE>

                  COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT

     This Agreement is entered into as of December     , 1997 (the "Effective
Date"), by and between NEUROCRINE BIOSCIENCES INC., a Delaware corporation
having an office at 3050 Science Park Road, San Diego, California 92121
("Neurocrine"), and RIGEL, INC., a Delaware corporation having an office at
772 Lucerne Drive, Sunnyvale, California 94086 ("Rigel").

                                       RECITALS

     WHEREAS, Neurocrine has an active research program in the area of
neurodegeneration and has developed a substantial compound library and drug
screening and medicinal chemistry capabilities;

     WHEREAS, Rigel has certain intellectual property and expertise
pertaining to the discovery, and identification of molecular targets
associated with signal transduction pathways; and

     WHEREAS, Neurocrine and Rigel desire to establish a collaboration for
the discovery, development and commercialization of (a) novel protein targets
involved in glial cell and macrophage activation, and (b) small molecule
inhibitors of protein:protein interactions involving proteins other than
those involved in glial cell activation (the "Collaboration"), and to reflect
their mutual understanding within this definitive Collaborative Research and
Development Agreement (the "Collaboration Agreement" or the "Agreement");

     NOW, THEREFORE, in consideration of the foregoing and the covenants and
promises contained in this Collaborative Agreement, the parties agree as
follows:

                                     AGREEMENT

I.   DEFINITIONS

     1.1   "AFFILIATE" means, as to a party to this Agreement, any
corporation, company, partnership, joint venture or other entity which
controls, is controlled by, or is under common control with, such party. For
purposes of this Section 1.1, control shall mean (without limitation) in the
case of corporate entities, the direct or indirect ownership of at least
fifty percent (50%) of the stock or participating shares entitled to vote for
the election of directors.

     1.2   "ANNUAL RESEARCH PLAN" means a plan approved by the Steering
Committee detailing the scope, level and extent of the Research and
Development, the specific technical and scientific responsibilities of each
party for each party for each one-year period during the Research and
Development Period, as described in Section 3.2.

     1.3   "COLLABORATION PRODUCTS" means collectively, Rigel Collaboration
Products and Neurocrine Collaboration Products.

                                      1.

<PAGE>

     1.4    "CONFIDENTIAL INFORMATION" means any proprietary information,
including the Neurocrine Technology and Rigel Technology, and any other
information relating to any research project, work in process, future
development, scientific, manufacturing, marketing, business plan, financial
or personnel matter relating to either party, its present or future products,
sales, suppliers, customers, employees, investors or business that one party
discloses to the other party during the term of this Agreement, whether in
oral, written, graphic or electronic form.

     1.5   "DEVELOPMENT MOLECULES" means any small molecule included in the
Neurocrine library or produced in the course of Neurocrine's performance of
medicinal chemistry on a small molecule included in the Neurocrine Chemical
Library pursuant to Section 2.3, which small molecule is screened against a
Rigel Target and is determined by the Research Committee to have an EC(50) of
less than 1 uM against such target. Development Molecules exclude Peptide
Antagonists.

     1.6   "EUROPE" shall mean the United Kingdom, Germany, France, Italy,
Spain and Switzerland.

     1.7   "JOINT TECHNOLOGY" means any and all discoveries, modifications,
improvements, know-how, trade secrets, inventions (whether or not
patentable), patent applications and patents (including, without limitation,
all substitutions, divisionals, reissues, reexaminations, continuations,
continuations-in-part and inventors' certificates and all foreign
counterparts of the foregoing), data, information or physical, chemical or
biological material useful or necessary to the development or
commercialization of Collaboration Products that is developed by Neurocrine
and Rigel jointly during the term of this Agreement as a result of Research
and Development under the Annual Research Plan. Ownership of Joint Technology
shall be determined in accordance with Article 6.

     1.8   "MAJOR COUNTRIES" means the United States, Europe, Japan and Canada.

     1.9   "NEUROCRINE CHEMICAL LIBRARY" means the library of chemical
compounds that Neurocrine owns or controls during the Research and
Development Period. For the purposes of this Agreement, the Neurocrine
Chemical Library shall be assumed to be approximately one hundred thousand
(100,000) compounds during the first year of the Collaboration, and
approximately one hundred twenty-five thousand (125,000) compounds during the
second year of the Collaboration, and shall be deemed to exclude any
compounds that Neurocrine has licensed to a third party prior to the
Effective Date and any compounds that Neurocrine is precluded from providing
to Rigel under this Agreement by reason of contractual or other proprietary
flights of a third party.

     1.10  "NEUROCRINE COLLABORATION PRODUCTS" means any product
incorporating or discovered utilizing a Protein Target or a Peptide
Antagonist.

     1.11  "NEUROCRINE TECHNOLOGY" means any and all discoveries,
modifications, improvements, know-how, trade secrets, inventions (whether
or not patentable), patent

                                      2.

<PAGE>

applications and patents (including, without limitation, all substitutions,
divisionals, reissues, reexaminations, continuations, continuations-in-part
and inventors' certificates and all foreign counterparts of the foregoing),
data, information or physical, chemical or biological material useful or
necessary to the development or commercialization of Collaboration Products
that is owned or licensed (with a right to sublicense) by Neurocrine as of
the Effective Date or solely made or developed by Neurocrine during the
Research and Development of Collaboration Products pursuant to this Agreement.

     1.12  "PROTEIN TARGET" means an enzyme, receptor, transducer or
transcription factor or other molecule identified during the performance of
the Research and Development that the Research Committee determines, based
upon data generated during the Research and Development, is a molecule
primarily involved in glial cell activation. Protein Targets shall exclude
Rigel Targets.

     1.13  "PARTY" means Neurocrine or Rigel or their respective Affiliates.

     1.14  "PEPTIDE ANTAGONISTS" means peptides identified or produced by
Rigel pursuant to Section 2 that the Research Committee determines, based upon
data generated during the Research and Development, to have activity against
one or more Protein Targets. Peptide Antagonists exclude Development Molecules.

     1.15  "RESEARCH AND DEVELOPMENT" means the collaborative activities
conducted by the parties during the Research and Development Period pursuant
to this Agreement targeted toward the generation, identification, production
and characterization of Rigel Targets, Protein Targets, Peptide Antagonists
and Development Molecules.

     1.16  "RESEARCH AND DEVELOPMENT PERIOD" means the period commencing upon
the Effective Date and terminating upon the second anniversary of the Effective
Date, during which period the parties shall conduct Research and Development.
The parties may extend the Research and Development Period for additional one
(1) year periods upon mutually acceptable terms.

     1.17  "RIGEL COLLABORATION PRODUCTS" means any product incorporating or
discovered utilizing Rigel Target or a Development Molecule.

     1.18  "RIGEL TARGET" means an enzyme, receptor, transducer, transcription
factor or other molecule that the Research Committee determines, based upon
data generated during the Research and Development, is specifically associated
primarily with processes other than glial cell activation. Rigel Targets
exclude Protein Targets.

     1.19  "RIGEL TECHNOLOGY" means any and all discoveries, modifications,
improvements, know-how, trade secrets, inventions (whether or not patentable),
patent applications and patents (including, without limitation, all
substitutions, divisionals, reissues, reexaminations, continuations,
continuations-in-part and inventors' certificates and all foreign

                                      3.

<PAGE>

counterparts of the foregoing), data, information or physical, chemical or
biological material useful or necessary to the development or commercialization
of Collaboration Products that is owned or licensed (with a right to sublicense)
by Rigel as of the Effective Date or solely made or developed by Rigel during
the Research and Development of Collaboration Products performed pursuant to
this Agreement.

     1.20  "STEERING COMMITTEE" means the committee established under Section 3
of this Agreement.

2.   RESEARCH AND DEVELOPMENT COLLABORATION

     2.1   OVERVIEW. The primary purpose of the Collaboration is to conduct
Research and Development toward the discovery and development of Collaboration
Products in accordance with the Annual Research Plan. To that end, it is
contemplated by the parties that:

           (a)  Neurocrine will have primary responsibility for supplying
certain cell lines necessary for the study of glial cell activation, providing
small molecule compounds from the Neurocrine Chemical Library, performing
limited medicinal chemistry as required by the Annual Research Plan, and
conducting certain screening and secondary assays and screening compounds from
the Neurocrine Chemical Library against Rigel Targets;

           (b)  Neurocrine and Rigel will share responsibility for applying the
Rigel Technology to develop an appropriate glial cell assay system to identify
Protein Targets and Peptide Antagonists; and

           (c)  Rigel will have primary responsibility for identifying and
providing Protein Targets, identifying and sequencing gene(s) coding for the
Protein Targets, and generating, identifying and providing Peptide Antagonists
of such Protein Targets. Rigel will also have responsibility for providing
Rigel Targets to Neurocrine for screening purposes. It is understood that the
individual and joint responsibilities will be set forth in detail in the Annual
Research Plan to be developed pursuant to Section 3.2.

     2.2   IDENTIFICATION AND TRANSFER OF PROTEIN TARGETS. The parties shall
use diligent efforts to identify and transfer to Neurocrine one or more
"primary" Protein Targets that the Research Committee determines, based upon
the activity of such target in glial cell function assays performed during the
Research and Development, to be the best targets against which to screen small
molecules for activity. To this end, within the first year of the
Collaboration, Rigel shall use diligent efforts to identify and provide to
Neurocrine at least six (6) Protein Targets, the genes encoding those Protein
Targets, and Peptide Antagonists active against such Protein Targets, unless
the Steering Committee otherwise provides in the Annual Research Plan. In the
event that Rigel is unable, using such diligent efforts, to provide the Protein
Targets, genes encoding the Protein Targets and/or Peptide Antagonists within
the first year of the Collaboration, Rigel shall continue to use diligent
efforts to provide such biological materials as soon as possible thereafter.

                                      4.

<PAGE>

     2.3   TRANSFER OF DEVELOPMENT MOLECULE TECHNOLOGY.

           (a)  Within the first year of the Collaboration, Rigel may provide
to Neurocrine a maximum of three (3) Rigel Targets that Neurocrine shall screen
against the Neurocrine Chemical Library. Similarly, during the second year of
the Collaboration, Rigel may provide to Neurocrine a maximum of another
three (3) Rigel Targets for the purposes of screening against the Neurocrine
Chemical Library. In no instance shall Neurocrine be obligated to screen a Rigel
Target that it believes in good faith to be in direct competition with a
Neurocrine research and development program existing at the time of the request.
All Rigel Targets shall be formatted in 96-well plates in an assay suitable for
high throughput screening. Within six (6) months of receipt of a Rigel Target,
Neurocrine shall screen such Rigel Targets as directed by the Research
Committee and provide Rigel with the results of such screen. In the event Rigel
provides more than two Rigel Targets to Neurocrine in any sixty (60) day period,
Neurocrine shall have the right to extend the time period within which it must
provide the results of the screen by an additional sixty (60) days.

           (b)  Based upon the results of the foregoing screening activities,
Rigel may select one (1) Rigel Target in each of the two years of the
Research and Development Period. During the second year of the Collaboration,
Neurocrine shall devote one full-time equivalent (FTE) for the purpose of
performing medicinal chemistry on molecules in the Neurocrine Chemical
Library that the Research Committee determines are active against the Rigel
Target and most suitable for structure-activity relationship development, and
perform additional appropriate screening to provide Rigel with a Development
Molecule prior to expiration of the Research and Development Period. Once a
Development Molecule has been identified, Neurocrine shall no longer be
obligated to expend any additional effort or resources on such Rigel Target
or Development Molecule. In the event that Neurocrine, in its discretion,
determines that it is unable to devote the services of one full-time
equivalent (FTE) to such medicinal chemistry activities during the second
year of the Collaboration, Neurocrine may elect to provide Rigel with a
portion of the Neurocrine Chemical Library (hereinafter the "Sample Library")
in lieu of the performance of such services. The Sample Library shall consist
of approximately one hundred microliters (100 uL) of a ten millimolar (10mM)
stock solution of any compound then existing in the Neurocrine Chemical
Library, for which Neurocrine has in its possession a quantity of at least 2
milligrams, on a compound-by-compound basis. The Sample Library shall also
include any structural information Neurocrine has in its possession with
regard to the transferred compounds. At the end of the second year of the
Collaboration (or earlier as provided above), Neurocrine shall provide to
Rigel the Sample Library to allow Rigel to conduct internal screening
activities, excluding the screening of any targets which Neurocrine is, or
reasonably anticipates, itself screening, as determined at the time of
transfer. For purposes of clarity, at the time of transfer Neurocrine shall
provide Rigel with a list of the targets as to which screening of the Sample
Library is prohibited.

     2.4   CONDUCT OF RESEARCH AND DEVELOPMENT. The parties will conduct their
respective Research and Development activities under the Annual Research Plan
in good

                                      5.

<PAGE>

scientific manner and in compliance with all applicable governmental,
regulatory and legal requirements. Neurocrine and Rigel will each use their
good faith scientific and business judgment to allocate sufficient time,
effort, equipment and facilities to. the Collaboration to achieve the
objectives of the Collaboration consistent with the terms of this Agreement
and the recommendations of the Steering Committee, as provided in Section 3
below.

     2.5   VISIT OF FACILITIES. Representatives of either party may, upon
reasonable notice and at a frequency reasonably acceptable to the Other party
during normal business hours (a) visit the facilities where the Research and
Development is being conducted; and (b) consult informally, during such visits
and by telephone, with personnel of the other party performing the Research
and Development. Each party shall bear its own expenses with regard to any such
visits. If requested by the other party, Neurocrine and Rigel shall cause
appropriate individuals working on the Research and Development to be available
for meetings at the location of the facilities where such individuals are
employed at times reasonably convenient to each party.

     2.6   DISCLOSURE OF DATA. The parties will promptly provide to each
other all data generated during the Research and Development, including,
without limitation, all Neurocrine Technology, Joint Technology and Rigel
Technology arising during the Research and Development Period.

3.   STEERING COMMITTEE

     3.1   FORMATION. The parties will promptly after the Effective Date form a
Steering Committee having six members, with an equal number of representatives
from each of Neurocrine and Rigel. Each party may replace its respective
representatives on the Steering Committee from time to time upon written notice
to the other party.

     3.2   MEETING AND RESPONSIBILITIES.

           (a)  Within ninety (90) days from execution of this Agreement, the
Steering Committee shall formulate and approve an Annual Research Plan which
shall guide each party's activities through December 31, 1998. The Steering
Committee will meet regularly during the Research and Development Period to:
(i) set objectives for the Research and Development; (ii) assess the level
and extent of the Research and Development activities to be conducted by each
party; (iii) review the progress of the Research and Development; (iv) oversee
patent matters relating to Joint Technology and any Rigel Technology or
Neurocrine Technology to be assigned pursuant to Section 6.3; (v) ensure that
the designation of all Rigel Targets, Protein Targets, Peptide Antagonists and
Development Molecules is documented and is consistent with the definitions
provided herein, and resolve any disputes regarding such designations;
(vi) oversee the extent and timing of any technology transfer necessary or
appropriate for the Research and

                                      6.

<PAGE>

Development; and (vii) encourage and facilitate ongoing cooperation between
the parties. Meetings of the Steering Committee will take place at mutually
agreed upon times and locations. From time to time, the Steering Committee
may establish subcommittees (including a Research Committee responsible for
directing the parties' day to day Research and Development activities) to
oversee particular projects or activities, and such additional subcommittees
shall be staffed as designated by the Steering Committee.

           (b)  By September 1, 1998, Neurocrine and Rigel shall submit to one
another their respective proposals concerning the Research and Development to
be conducted during the next calendar year. Thereafter, Neurocrine and. Rigel
shall jointly prepare proposed revisions to the draft Annual Research Plan for
submission to the Steering Committee for approval. The Steering Committee shall
review the proposal as soon as possible after receipt, and shall establish and
approve a final Annual Research Plan for the following calendar year prior to
or on November 15, 1998. The Steering Committee may amend the Annual Research
Plan from time to time as it deems necessary or appropriate. The parties shall
alternate the responsibility of preparing and distributing the minutes of such
Steering Committee meetings, with Neurocrine preparing the minutes of the first
meeting. All such meeting minutes should, whenever possible, be distributed to
the parties within twenty-one (21) days from the date of the meeting, and
should include any changes to the Annual Research Plan, and a summary of any
inventions, discoveries or results achieved under this Agreement which should
be deemed to be Joint Technology. If necessary or desired, each party may
consult with its respective patent counsel prior to rendering any such
designation of results as Joint Technology. The Steering Committee shall
attempt to resolve any disagreements regarding whether a given technology
should be designated as Joint Technology, Rigel Technology or Neurocrine
Technology pursuant to Section 6.6.

     3.3   DISAGREEMENTS. Decisions of the Steering Committee shall be by a
majority vote. If no majority vote is obtained with respect to any issue, the
matter will be referred to the Chief Executive Officer of each party or such
other senior executive designated by a party who is reasonably acceptable to
the other party and who has decision-making authority. Such persons shall
meet and attempt to resolve the matter in good faith. Any disputes that remain
unresolved by such executives shall be submitted for resolution as provided in
Section 9.3.

4.   COLLABORATION FUNDING

     4.1   RESEARCH AND DEVELOPMENT FUNDING. Neurocrine and Rigel shall each
be responsible for their own costs associated with activities within the
Annual Research Plan.

                                      7.

<PAGE>

5.   LICENSES

     5.1   RESEARCH LICENSE TO RIGEL. Neurocrine hereby grams to Rigel a
non-exclusive, worldwide, royalty-free license, without the right to
sublicense, under Neurocrine's interest in the Neurocrine Technology, Joint
Technology and any Rigel Technology that may be assigned to Neurocrine
pursuant to Section 6.5, solely to the extent necessary or appropriate for
Rigel to conduct Research and Development of Collaboration Products pursuant
to this Agreement.

     5.2   RESEARCH LICENSE TO NEUROCRINE. Rigel hereby grants to Neurocrine
a non-exclusive, worldwide, royalty-free license, without the right to
sublicense, under Rigel's interest in the Rigel Technology, Joint Technology
and any Neurocrine Technology that may be assigned to Rigel pursuant to
Section 6.5, solely to the extent necessary or appropriate for Neurocrine to
conduct Research and Development of Collaboration Products pursuant to this
Agreement.

     5.3   COMMERCIALIZATION LICENSE TO NEUROCRINE. Rigel hereby grants to
Neurocrine an exclusive, worldwide, royalty free license, with the right to
sublicense, under Rigel's interest in any applicable intellectual property
rights within the Rigel Technology or the Joint Technology solely to develop,
make, use, sell, offer for sale and import Neurocrine Collaboration Products.

     5.4   COMMERCIALIZATION LICENSE TO RIGEL. Neurocrine hereby grants to
Rigel an exclusive, worldwide, royalty-free, license, with the right to
sublicense, under Neurocrine's interest in any applicable intellectual
property rights within the Neurocrine Technology or the Joint Technology
solely to develop, make, use, sell, offer for sale or import Rigel
Collaboration Products.

6.   PATENT MATTERS

     6.1   OWNERSHIP. Subject to Section 6.5, as determined in accordance with
the rules of inventorship under U.S. law, each party shall have sole ownership
of all inventions made solely by its employees or other agents during the term
of this Agreement, which inventions shall be Rigel Technology if made solely by
Rigel's employees or agents or Neurocrine Technology if made solely by
Neurocrine's employees or agents. The parties shall each own a fifty percent
(50%) undivided interest (without accounting) in all inventions made jointly by
the parties' employees or other agents, subject to any licenses granted
pursuant to this Agreement, which inventions shall be Joint Technology.
Specifically, Neurocrine shall have sole ownership and control of the Neurocrine
Technology, and Rigel shall have sole ownership and control of Rigel Technology,
subject to any licenses granted pursuant to this Agreement. The parties agree
that they each shall enter into agreements with their respective employees and
other agents providing

                                      8.

<PAGE>

that, to the maximum extent permitted by applicable law, such employees and
other agents shall assign (or be obligated to assign) to the party hereto
which acts as their employer or principal, the ownership and control of all
inventions conceived or reduced to practice by such employees and agents in
the course of their employment for, or within the scope of the agency
relationship with, each party hereto. Any disputes regarding the designation
of inventions as Neurocrine Technology, Rigel Technology or Joint Technology
shall be submitted for resolution by the Steering Committee.

     6.2   PROSECUTION OF PATENTS CONSTITUTING RIGEL TECHNOLOGY. Rigel shall
prepare, file, prosecute and maintain patent applications and/or patents
worldwide, in accordance with Section 6.6, for those inventions within the
Rigel Technology and any inventions assigned to Rigel pursuant to Section
6.5. Rigel shall use its best efforts, consistent with its own internal
filing procedures, to obtain letters patent on patentable Rigel Technology in
all Major Countries and, where possible and appropriate, worldwide.

     6.3   PROSECUTION OF PATENTS CONSTITUTING NEUROCRINE TECHNOLOGY AND
JOINT TECHNOLOGY. Neurocrine shall prepare, file, prosecute and maintain
patents and/or patent application worldwide, in accordance with Section 6.6,
for those inventions within the Neurocrine Technology and within the Joint
Technology and any inventions included in the Rigel Technology that are
assigned to Neurocrine pursuant to Section 6.5. Neurocrine shall use its best
efforts, consistent with its own internal filing procedures, to obtain
letters patent in all Major Countries and, where possible and appropriate,
worldwide.

     6.4   COOPERATION IN PATENT MATTERS. Consistent with Section 6.6 below,
the parties agree to cooperate with each other as necessary or appropriate in
the preparation, filing and prosecution of patent applications pursuant to
Sections 6.2, 6.3 and 6.5, including providing one another a reasonable
opportunity to review and comment on any patent application to be filed in
the U.S. or in any other country. All costs associated with the preparation,
filing, prosecution and maintenance of patent applications and patents
coveting jointly owned Joint Technology shall be shared equally by the
parties.

     6.5   TRANSFER OF CERTAIN PATENTS CONSTITUTING NEUROCRINE TECHNOLOGY,
RIGEL TECHNOLOGY OR JOINT TECHNOLOGY. Notwithstanding Sections 6.1 and 6.2,
Rigel shall assign its interest in any inventions included in the Rigel
Technology and any Joint Technology that is solely related to a Protein
Target or to a Peptide Antagonist to Neurocrine, and Neurocrine shall
thereafter prepare, file, prosecute and maintain patents and/or patent
applications worldwide for all such inventions, consistent with the
provisions of Section 6.3. Similarly, notwithstanding Sections 6.1 and 6.3,
Neurocrine shall assign its interest in any invention included in the
Neurocrine Technology and any Joint Technology that is solely related to a
Development Molecule or to a Rigel Target to Rigel, and Rigel shall
thereafter prepare, file, prosecute and maintain patents and/or patent
applications worldwide for all such inventions, consistent with the
provisions of Section 6.2.

                                      9.

<PAGE>

     6.6   DISCLOSURE OF INVENTIONS AND REVIEW OF PATENT APPLICATIONS. Each
party shall provide the other with a copy of a summary of any disclosure of an
invention (including those inventions included in the Joint Technology) arising
in the course of the Collaboration as soon as is reasonably practical after
such party recognizes such invention to allow the other party an opportunity to
comment upon the subject matter and upon the ownership and inventorship of the
invention. Subsequent to the provision of such a summary, designation of an
invention as Rigel Technology, Neurocrine Technology or Joint Technology, and
the determination of the ownership of such invention, the party responsible for
filing a patent application on such invention pursuant to Section 6 shall
provide the other party with a copy of any draft patent application directed
toward the invention in order. In addition, Neurocrine shall provide to Rigel a
copy of all amendments or substantive communications relating to jointly owned
Joint Technology sufficiently in advance of any relevant deadline or
anticipated submission date to allow Rigel a reasonable opportunity to evaluate
and comment upon any such application, amendment or substantive communication.

     6.7   ENFORCEMENT OF PATENTS BY A SINGLE PARTY. (a) Rigel shall have the
first right (but not the obligation) to enforce the patents included in the
Rigel Technology and any patents included in the Neurocrine Technology or Joint
Technology that are assigned to Rigel pursuant to section 6.4 against third
party infringement, and (b) Neurocrine shall have the first right (but not the
obligation) to enforce the patents included within the Neurocrine Technology or
Joint Technology (other than those patents included in the Joint Technology or
Neurocrine Technology that are assigned to Rigel pursuant to Section 6.5)
against third party infringement. In the event that the party with the first
right to enforce a patent pursuant to this Section 6.6 fails to commence
enforcement or otherwise terminates the alleged infringement within six months
after that party has learned of the alleged infringement, the other party shall
have the right, but not the obligation, to bring and control any such action
using counsel of its own choice and at its own expense.

     6.8   JOINT ENFORCEMENT OF PATENTS. If one party commences enforcement
proceedings pursuant to Section 6.6, the other party may elect upon written
notice to the enforcing party to join in the action in order to provide
reasonable assistance and to share in the costs and expenses associated with
the action. Any monetary awards recovered through the action shall first be
applied to fees and expenses, and the remainder shared pro rata based upon
the relative financial contribution of the parties to such fees and expenses.

     6.9   THIRD PARTY INFRINGEMENT ACTIONS. If a party receives notice of
any suit or claim alleging that the conduct of the activities within this
Agreement infringes the proprietary rights of a third party, the parties
shall promptly meet to discuss and decide on an appropriate response.

                                      10.

<PAGE>

7.   CONFIDENTIALITY

     7.1   CONFIDENTIALITY OBLIGATION. During the term of this Agreement and
for a period of five years thereafter, each party hereto shall maintain in
confidence all Confidential Information disclosed to it by the other party.
Neither party will use, disclose or grant the use of such Confidential
Information except as expressly authorized by this Agreement. To the extent
that disclosure is authorized by this Agreement, the disclosing party will
obtain prior agreement from its employees, agents, consultants or investigators
to whom disclosure is to be made to hold in confidence and not make use of such
information for any purpose other than those permitted by this Agreement. Each
party will use at least the same standard of care as it uses to protect its own
proprietary and trade secret information to ensure that such employees, agents,
consultants and investigators do not disclose or make any unauthorized use of
such Confidential Information. Each party will promptly notify the other upon
discovery of any unauthorized use or disclosure of the Confidential Information.

     7.2   EXCEPTIONS. The obligations of confidentiality contained in
Section 7.1 will not apply to the extent that it can be established by the
party receiving Confidential Information (the "Receiving Party") by competent
proof that such Confidential Information:

           (a)  was already known to the Receiving Party, other than under an
obligation of confidentiality with respect thereto, at the time of receipt from
the other party;

           (b)  was generally available to the public or otherwise part of the
public domain at the time of its receipt from the other party;

           (c)  becomes generally available to the public or otherwise part
of the public domain after its disclosure and other than through any act or
omission of the Receiving Party in breach of this Agreement; or

           (d)  was received by the Receiving Party, other than under an
obligation of confidentiality, by a third party without breach of any
obligations of confidentiality with respect thereto.

     7.3   AUTHORIZED DISCLOSURE. Each party may disclose the Confidential
Information to the extent such disclosure is reasonably necessary in filing
or prosecuting patent applications, prosecuting or defending litigation, or
complying with applicable laws, governmental regulations, or court orders
provided that if such party is required to make any such disclosure of the
Confidential information it will to the extent practicable give reasonable
advance notice to the other party of such disclosure requirement and, except
to the extent inappropriate in the case of patent applications, will use all
reasonable efforts to secure confidential treatment of such information
required to be disclosed, subject to the limitations on disclosure set forth
in Section 7.4 (b).

     7.4  PUBLICATION.

                                      11.

<PAGE>

           (a)  During the term of this Agreement and for a period of five
(5) years thereafter, Neurocrine and Rigel each acknowledge the other party's
interest in publishing certain of its results to obtain recognition within the
scientific community and to advance the state of scientific knowledge. Each
party also recognizes the mutual interest in obtaining valid patent protection
and maintaining as confidential any Confidential Information or non-patentable
information which would have commercial value when undisclosed and maintained
as a trade secret. Consequently, if a party, its employees or consultants
desire to make a disclosure (including both written publications and oral
presentations made in the absence of a contractual obligation of
confidentiality) relating to work performed by such party (the "Publishing
Party") as part of the Research and Development, it shall transmit to the other
party (the "Reviewing Party") a copy of the proposed written publication at
least sixty (60) days prior to submission for publication, or an outline of
such oral presentation at least thirty (30) days prior to the anticipated date
of presentation. The Reviewing Party shall have the right (i) to propose
modifications to the publication or presentation to protect the patentability
of inventions, to maintain a trade secret or to protect other Confidential
Information of a party and (ii) to request a delay in publication or
presentation for a reasonable period of time as provided in Section 7.4(b) in
order to protect patentable information.

           (b)  If the Reviewing Party requests such a delay, the Publishing
Party shall delay the submission of the publication or the oral presentation
for a period of up to ninety (90) days to allow one or both parties to file
patent applications coveting information included in the publication or
presentation in accordance with Section 6. If the Reviewing Party reasonably
claims that such information, whether patentable or not, either is Confidential
Information of the Reviewing Party or may have significant commercial value and
can be maintained as a trade secret, the Publishing Party shall publish or
disclose only such information which would not adversely affect the
confidentiality of such Confidential Information or the commercial value of
such trade secret. Upon the expiration of sixty (60) or thirty (30) day review
period (as the case may be) set forth in Section 7.4(a), the Publishing Party
shall be free to proceed with the written publication or the presentation, as
applicable, unless the Reviewing Party has requested a further delay or a
modification described in this Section 7.4(b).

8.   TERM AND TERMINATION OF THE AGREEMENT

     8.1   TERM. Unless earlier terminated as provided below, the term of
this Agreement shall commence upon the Effective Date and terminate
concurrently With the termination of the Research and Development Period.

     8.2   TERMINATION.

           (a)  Each party will have the right to terminate this Agreement
(i) in the event of insolvency or bankruptcy of the other party, or (ii) after
written notice to the other that the

                                      12.

<PAGE>

other is in breach of any material term of this Agreement, unless the other
party cures such breach before the expiration of sixty (60) days from the
date of receipt of such notice.

           (b)  Either party may elect to terminate this Agreement during the
Research and Development Period prior to its expiration pursuant to Section
8.1 by providing to the other ninety (90) days written notice. In the event
that the Agreement is terminated prior to the second anniversary of the Research
and Development Period, the parties will meet and determine in good faith the
identity and disposition of all intellectual property rights and biological and
chemical materials generated up until the time of termination in accordance with
Section 6; provided, however, that the parties will negotiate in good faith the
disposition of any intellectual property rights and biological and chemical
materials that are not covered by the provisions of Section 6. Expiration or
termination of this Agreement shall not relieve the parties of any obligation
accruing prior to such expiration or termination.

     8.3   EFFECTS OF EXPIRATION OR TERMINATION OF THE RESEARCH AND
DEVELOPMENT PERIOD. Upon expiration of the Research and Development Period or
any termination of this Agreement prior to the expiration of the Research and
Development Period, all remaining chemical and biological materials included
in the Rigel Technology that are in Neurocrine's possession at the time of
expiration or termination of the Research and Development Period shall be
returned to Rigel, and all remaining chemical and biological materials included
in the Neurocrine Technology that are in Rigel's possession at the time of
expiration or termination of the Research and Development Period shall be
returned to Neurocrine, except to the extent that the parties may otherwise
agree during discussions conducted pursuant to Section 8.2 (b).

     8.4   EFFECTS OF EXPIRATION OR TERMINATION OF THE AGREEMENT. Sections 6,
7, 8, 9.1, 9.2, 9.3, 9.9 and 9.10 shall survive any expiration or termination
of this Agreement. Upon any termination of this Agreement prior to its
expiration pursuant to Section 8.1. the commercialization licenses granted
pursuant to Sections 5.3 and 5.4 shall survive such termination of this
Agreement; provided, however, that if this Agreement is terminated for material
breach by Neurocrine, then the license granted pursuant to Section 5.3 shall
not survive such termination, and further provided that if this Agreement is
terminated for material breach by Rigel, then the license granted pursuant to
Section 5.4 shall not survive such termination.

9.   MISCELLANEOUS PROVISIONS

     9.1   INDEMNIFICATION.

           (a)  Rigel agrees to indemnify, hold harmless and defend the
other, its officers, agents, and Affiliates (the "Neurocrine Indemnitees")
against any and all claims, suits, losses, damage, costs, fees and expenses
of or by third parties (collectively, "Claims") for damage to persons or
property resulting directly or indirectly from Rigel's, its Affiliates or its
sublicensee's actions in connection with its performance under this Agreement
or the manufacture, use, sale offer for sale or import of Rigel Collaboration
Products, except to the extent such Claims arise out of or result from the
negligence, recklessness or willful acts or omissions of the Neurocrine

                                      13.

<PAGE>

Indemnitees or arise out of or result from any breach of this Agreement by
the Neurocrine Indemnitee. Any Neurocrine Indemnitee shall give prompt notice
to Rigel of any Claims brought or filed against such Neurocrine Indemnitee,
and Rigel shall assume the defense of such Claims with counsel reasonably
satisfactory to the Neurocrine Indemnitee. Rigel will not be subject to any
liability for any settlement of such Claims made by a Neurocrine Indemnitee
without Rigel's consent (not to be unreasonably withheld). The Neurocrine
Indemnitee may retain separate counsel with respect to any such Claims at its
own expense.

           (b)  Neurocrine agrees to indemnify, hold harmless and defend the
other, its officers, agents, and Affiliates (the "Rigel Indemnitees") against
any and all claims, suits, losses, damage, costs, fees and expenses of or by
third parties (collectively, "Claims") for damage to persons or property
resulting directly or indirectly from Neurocrine's, its Affiliates or its
sublicensee's actions in connection with its performance under this Agreement
or the manufacture, use, sale offer for sale or import of Neurocrine
Collaboration Products, except to the extent such Claims arise out of or
result from the negligence, recklessness or willful acts or omissions of the
Rigel Indemnitees or arise out of or result from any breach of this Agreement
by the Rigel Indemnitee. Any Rigel Indemnitee shall give prompt notice to
Neurocrine of any Claims brought or filed against such Rigel Indemnitee, and
Neurocrine shall assume the defense of such Claims with counsel reasonably
satisfactory to the Rigel Indemnitee. Neurocrine will not be subject to any
liability for any settlement of such Claims made by a Rigel Indemnitee
without Neurocrine's consent (not to be unreasonably withheld). The Rigel
Indemnitee may retain separate counsel with respect to any such Claims at its
own expense.

     9.2   DISCLAIMER OF WARRANTIES. THE RIGEL TECHNOLOGY AND THE NEUROCRINE
TECHNOLOGY ARE PROVIDED BY RIGEL AND NEUROCRINE, RESPECTIVELY, "AS IS" AND
EACH PARTY EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING
WITHOUT LIMITATION WARRANTIES OF DESIGN, MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE, NONIFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF
THIRD PARTIES OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES
WITH RESPECT THERETO. Without limitation, each party expressly does not warrant
the success of any Research and Development activities or the safety or
usefulness of any technology it provides hereunder.

     9.3   DISPUTE RESOLUTION. If a dispute arises between the parties
relating to the interpretation or performance of this Agreement or the
grounds for the termination thereof, the parties agree to hold a meeting,
attended by individuals with decision-making authority regarding the dispute,
to attempt in good faith to negotiate a resolution of the dispute prior to
pursuing other available remedies. If, within 30 days after such meeting, the
parties have not succeeded in negotiating a resolution of the dispute, such
dispute shall be submitted to final and binding arbitration under the then
current Licensing Agreement Arbitration Rules of the American Arbitration
Association ("AAA"), with a panel of three arbitrators with significant
experience in the biopharmaceutical industry conducting proceedings in San
Diego, California. Such arbitrators

                                      14.

<PAGE>

shall be selected by mutual agreement of the parties or, failing such
agreement, shall be selected according to the aforesaid AAA rules. The parties
shall bear the costs of arbitration equally unless the arbitrators, pursuant to
their right, but not their obligation, require the non-prevailing party to bear
all or any unequal portion of the prevailing party's costs. The decision by the
arbitrators shall be made within ninety (90) days after the selection of the
arbitrators. The decision of the arbitrators shall be final and may be sued on
or enforced by the party in whose favor it decides in any court of competent
jurisdiction at the option of such party. The arbitrators will be instructed to
prepare and deliver a written, reasoned opinion conferring their decision. The
rights and obligations of the parties to arbitrate any dispute relating to the
interpretation or performance of this Agreement or the grounds for the
termination thereof shall survive the expiration or termination of this
Agreement for any reason.

     9.4   FORCE MAJEURE. Neither party shall be held liable or responsible to
the other party nor shall either party be deemed to have defaulted under or
breached this Agreement for failure or delay in fulfilling or performing any
term of this Agreement (other than payment of monies due) when such failure or
delay is caused by or results from causes beyond reasonable control of the
affected party including but not limited to fire, floods, embargoes, war, acts
of war (whether war be declared or not), insurrections, riots, civil commotions,
strikes, lockouts or other labor disturbances, acts of God or acts, omissions or
delays in acting by any governmental authority, or earthquakes, provided that
the affected party uses reasonable efforts to overcome such failure or delay.

     9.5   ASSIGNMENT. This Agreement may not be assigned or otherwise
transferred, nor, except as expressly provided hereunder, may any rights or
obligations hereunder be assigned or transferred, by either party without the
written consent of the other party; provided, however, that either party may,
without such consent, assign this Agreement and its rights and obligations
hereunder (a) in connection with the transfer or sale of all or substantially
all of its business, if such assets include substantially all of the assets
relating to its performance of its obligations hereunder, (b) to a wholly owned
subsidiary or, (c) in the event of its merger or consolidation with another
company at any time during the term of this Agreement. Any purported assignment
in violation of this Section 9.5 shall be void. Any permitted assignee shall
assume all obligations of its assignor under this Agreement.

     9.6   PUBLICITY. The parties agree that neither party will originate any
news release or other public announcement, written or oral, or otherwise make
any disclosure relating to the existence or terms of or performance under
this Agreement without the prior written approval of the other party, except
as may otherwise be required by law, or as provided in Section 7.4.

     9.7   EXPORT LAWS. Each party hereby agrees that no technology or
information licensed from the other, and no product thereof, will be made
available or re-exported, directly or indirectly, except in compliance with
all applicable export laws and regulations.

     9.8   SEVERABILITY. Both parties hereby expressly agree and contract
that it is the intention of neither party to violate any laws, rules,
regulations, treaty or decision of any

                                      15.

<PAGE>

government agency or executive body thereof of any country or community or
association of countries. Should a court or governmental authority of competent
jurisdiction determine that one or more provisions of this Agreement are invalid
or unenforceable by reason of such a violation, then the parties hereto shall
attempt to substitute, by mutual consent, valid provisions for such invalid
provisions, which valid provisions closely approximate the economic effect of
the invalid provisions. If the parties are unable to formulate a mutually
acceptable provision to replace any invalid provision, then such invalid
provisions shall be severed from this Agreement and the invalidity of such
provision shall not affect the validity of the Agreement as a whole.

     9.9   NOTICES.  Any notice or report required or permitted to be given or
made under this Agreement by one of the parties hereto to the other shall be in
writing, delivered personally or by facsimile (and promptly confirmed by
telephone, personal delivery or courier) or courier, postage prepaid, addressed
to such other party at its address indicated on the first page of this Agreement
(to the attention of Gary Lyons, if to Neurocrine, and to the attention of James
Gower, if to Rigel), or to such other address as the addressee shall have last
furnished in writing to the address or and shall be effective upon receipt by
the addressee.

     9.10  APPLICABLE LAW. This Agreement shall be governed by and construed
in accordance with the laws of the State of California, without regard to its
choice of law provisions, and any applicable laws of the United States.

     9.11  ENTIRE AGREEMENT; AMENDMENT. This Agreement contains the entire
understanding of the parties with respect to the subject matter hereof. All
express or implied agreements and understandings, either oral or written,
heretofore made are expressly merged into and made a part of this Agreement.
This Agreement may be amended, or any term hereof modified, only by a written
instrument duly executed by both parties hereto.

     9.12  INDEPENDENT CONTRACTORS. It is expressly agreed that Neurocrine and
Rigel shall be independent contractors and that the relationship between the two
parties shall not constitute a partnership, joint venture or agency of any kind.
Neither party shall have the authority to make any statements, representations
or commitments of any kind, or to take any action, which shall be binding on the
other, without the prior written authorization of the other party to do so.

     9.13  WAIVER. The waiver by either party hereto of any right hereunder
or the failure to perform or of a breach by the other party shall not be deemed
a waiver of any other right hereunder or of any other breach or failure by said
other party whether of a similar nature or otherwise.

     9.14  COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                      16.

<PAGE>

          IN WITNESS WHEREOF, the parties hereto have duly executed this
Collaborative Agreement.

NEUROCRINE, INC.                        RIGEL, INC.

By:  /s/ Kevin C. Gorman                By:  /s/ James Gower
   -------------------------------         --------------------------------
       Kevin C. Gorman                         James Gower
Title: Senior Director,                 Title: Chief Executive Officer
       Business Development

                                      17.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]